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Many epidemiological studies have examined associations between birth defects (BDs) and
pediatric malignancy over the past several decades. Our objective was to conduct a system-
atic literature review of studies reporting on this association.
Methods
We used librarian-designed searches of the PubMed Medline and Embase databases to
identify primary research articles on pediatric neoplasms and BDs. English language articles
from PubMed and Embase up to 10/12/2015, and in PubMed up to 5/12/2017 following an
updated search, were eligible for inclusion if they reported primary epidemiological research
results on associations between BDs and pediatric malignancies. Two reviewers coded
each article based on the title and abstract to identify eligible articles that were abstracted
using a structured form. Additional articles were identified through reference lists and other
sources. Results were synthesized for pediatric cancers overall and for nine major pediatric
cancer subtypes.
Results
A total of 14,778 article citations were identified, of which 80 met inclusion criteria. Pediatric
cancer risk was increased in most studies in association with BDs overall with some notable
specific findings, including increased risks for CNS tumors in association with CNS abnormal-
ities and positive associations between rib anomalies and several pediatric cancer types.
Conclusions
Some children born with BDs may be at increased risk for specific pediatric malignancy
types. This work provides a foundation for future investigations that are needed to clarify
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specific BD types predisposing toward malignancy and possible underlying causes of both
BDs and malignancy.
Introduction
Pediatric cancer is diagnosed in>14,000 U.S. children per year from the ages of 0–19 years and
is the leading cause of disease-related death among children aged 1–14 years [1, 2]. Although a
few risk factors have been conclusively identified, including exposure to high dose radiation
and certain genetic syndromes, the etiology underlying most cases remains unknown.
Evidence accumulated over several decades suggests positive associations between birth
defects (BDs) and pediatric malignancy. BDs affect ~1 in 33 U.S. children and are defined as
“structural changes present at birth that can affect almost any part or parts of the body” [3].
BDs are often categorized as major and minor with major anomalies generally considered
those having “an adverse effect on the individual’s health, functioning or social acceptability”
and minor anomalies considered those having “limited social or medical significance”. Major
anomaly examples include spina bifida, cleft lip palate, and Down Syndrome [4]. Minor anom-
aly examples include low set ears, epicanthal folds, and simian crease [5]. Although certain
genetic syndromes are known to increase pediatric cancer risk (e.g. Down Syndrome and leu-
kemia), other BDs (including major and minor), independent of known cancer predisposition
syndromes, may also be associated with an increased risk.
Recent evidence suggests that 8.5% of children with cancer harbor germline mutations in
well-known cancer genes that predispose them to the development of early-onset malignancy
[6]. However, when considering a more broad predisposition definition including family his-
tory, co-morbidities, and types of pediatric cancer, up to about a third of children with cancer
may have a genetic predisposition [7]. Many pediatric cancer predisposition syndromes
involve defects in normal development and many pediatric cancers arise from immature cell
types (e.g. the “blastomas”). Thus, identifying and understanding connections between abnor-
mal fetal or childhood development and the risk of developing cancer will have implications
for surveillance, prognosis, risk stratification and potential personalized therapeutics.
To summarize evidence on associations between pediatric malignancy and BDs, we con-
ducted a systematic literature review to identify articles reporting primary human epidemio-
logical research. This work provides a foundation for future studies and may help to identify
high risk populations for malignancy among individuals with BDs that will enable improved
surveillance, mechanistic research, targeted treatment and outcomes.
Methods
Abbreviations used in this review are provided in Table 1. Our review followed the 2009 Pre-
ferred Reporting Method for Systematic Reviews (PRISMA) guidelines [8] (See S1 Checklist).
A summary of the review protocol is provided below.
Search strategy
We identified relevant articles in the Medline PubMed [9] and Embase [10] databases on 9/10/
2015 and 10/12/2015 using librarian designed search strategies. The review was updated on 5/
12/2017 using the PubMed database. (S1 Table). We also examined each article’s reference list
from those included in the review and consulted a well-known review published by the Inter-
national Agency for Cancer Research in 1999 for any additional studies [11]. Finally, the senior
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author conducted a few PubMed literature searches based on her expert opinion to identify
additional qualifying articles.
Eligibility criteria and review process
The citation lists obtained from each database search were evaluated for initial eligibility by
at least two coauthors (KA, JL, and KJ). We excluded review articles, editorial commentaries,
meeting abstracts, articles focused solely on syndromes with known genetic etiologies, on
treatment or clinical outcomes, solely on adults ( 18 years), and articles not providing
information on risks specific to children with the exception of the Gelberg et al. study that
reported risks for osteosarcoma from 0–24 years [12]. In addition, lab-based studies and case
reports/series without external comparison groups were excluded. Reviewers classified each
article initially based on title review (and abstract if eligibility was unclear from the title) as:
1) eligible, 2) unclear eligibility, and 3) ineligible. Following reconciliation of articles with
coding disagreement by the senior author and reviewers, articles assigned to category one
were abstracted.
Data collection
Data were abstracted from each article using a pre-designed form that captured: study popula-
tion, study design and description, sources of information on BDs and cancer, study inclusion
Table 1. Abbreviations.
Abbreviation Full name Abbreviation Full name
ALL Acute Lymphocytic Leukemia MDS Myelodysplastic Syndrome
AML Acute Myeloid Leukemia MPD Myeloproliferative Disease
ANLL Acute Non-Lymphoblastic Leukemia NB Neuroblastoma
AST Astrocytoma NHL Non-Hodgkin’s Lymphoma
BC British Columbia NOS Newcastle-Ottawa scale
BDs Birth Defects NA Not applicable
CBT Childhood brain tumors ND Not determined
CI Confidence Interval NR Not Reported
CNS Central Nervous System NRCT National Registry of Childhood Tumours
CPP Collaborative Perinatal Project NWTS National Wilms’ Tumor Study
DS Down syndrome OR Odds Ratio
EPD Ependymoma OS Osteosarcoma
ES Ewing’s Sarcoma PNET Primitive neuro-ectodermal tumor
GCT Germ cell tumors PRISMA Preferred Reporting Method for Systematic reviews
HB Hepatoblastoma RB Retinoblastoma
HD Hodgkin’s Disease RB Retinoblastoma
HGG High grade glioma RDD Random Digit Dialing
HL Hodgkin’s Lymphoma RMS Rhabdomyosarcoma
HM Hematologic malignancy RMS Rhabdomyosarcoma
HR Hazard Ratio RR Risk Ratio
IARC International Agency For Research On Cancer SNS Sympathetic Nervous System
ICD The International Classification of Diseases STS Soft Tissue Sarcomas
IRR Incidence Rate Ratio WAGR syndrome Wilms tumor-aniridia intellectual disability syndrome
LGG Low Grade Glioma WT Wilm’s tumor
LHT Lymphatic and hematopoietic tissues UPDB Utah Population database
MB Medulloblastoma
https://doi.org/10.1371/journal.pone.0181246.t001
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and exclusion criteria, age groups studied, birth years, cancer diagnosis years, BD case defini-
tion, BD types examined, cancer types examined, subject numbers, analysis method, measure
of association reported, and key findings. Any additional information relevant to interpreta-
tion of study results was captured in a comment field. To the extent possible, we abstracted the
number of subjects for each comparison group and included this information where the num-
bers were reported directly or required minimum assumptions to calculate. Any articles that
were identified as ineligible during the abstraction phase were subsequently excluded. During
our update of the review, we also abstracted information where reported on classification of
major and minor anomalies, maximum age at which BDs were ascertained, and cancer risks
by age. We did not attempt to reclassify anomalies from the original reports for summary
purposes.
Quality assessment
We employed a modified Newcastle-Ottawa Scale (NOS), designed for quality assessment of
observational studies [13], that uses a star assignment system to determine overall quality for
case-control, nested case-control, case-cohort, and cohort studies. Case series studies with
external comparison groups were not evaluated. Evaluation criteria are described briefly
below.
Case-control, nested case-control, and case-cohort studies. A) Selection. Up to four
stars were awarded to studies based on: 1) adequate case definition, 2) representativeness of
cases, 3) control selection, and 4) adequate control definition. A case definition was considered
adequate if cases were defined based on either clinical and/or histopathological validation of
their cancer diagnosis or were identified through cancer registry data. Cancer cases were con-
sidered representative if they were community/population-based versus hospital-based. For
control selection, a star was given if controls were selected from the same population as cases.
The control definition was considered adequate if the authors provided information to indi-
cate that controls did not have a history of the outcome.
B) Comparability between the groups. Up to two stars were awarded to studies matching
on or adjusting for maternal age and child’s sex, potential confounders of the association
between pediatric malignancy and BDs.
C) Ascertainment of the exposure. Up to three stars were awarded to studies if: 1) BDs
were ascertained through medical records, physical exam, or birth certificate data, 2) they used
the same method of BD ascertainment for cases and controls, and 3) they reported a similar
non-response rate for both cases and controls (<10% difference) or the study used registry
data for BD ascertainment.
Cohort studies. A) Selection. Up to four stars were awarded to studies based on: 1) repre-
sentativeness of the exposed cohort, 2) selection of the non-exposed cohort, 3) ascertainment
of exposure, and 4) demonstration that the outcome of interest was not present at the start of
the study. Studies were given one star each if the exposed cohort registry/population included
all children from a defined geographic region was representative of the community, if the non-
exposed cohort was drawn from the same community as the exposed cohort, if medical records
or BD registry information was used to identify exposed subjects or if the exposure was based
on birth certificate data, and if it was indicated that cancer was not present at the start of the
study.
B) Comparability. Comparability criteria were the same as for case-control studies.
C) Outcome. Up to two stars were awarded based on: 1) assessment of the outcome and 2)
follow-up length. One star was awarded if the outcome was assessed independently or through
medical records or record linkage (i.e. through administrative data through ICD codes). One
Pediatric cancer risk in association with birth defects: A systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0181246 July 27, 2017 4 / 56
star was given if the follow-up period was long enough for outcomes to occur (we set this
at 6 years with consideration for the age distribution of pediatric cancer).
Statistical methods
Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for case-
control studies where authors provided data for calculations but did not include these mea-
sures of association. To summarize the individual quality of each study, we computed the total
quality points by summing the number of stars received. To compare overall quality of cohort
studies vs. other study designs that differed in their maximum achievable quality points (8 for
cohort vs. 9 for case-control, nested case-control, and case-cohort studies), we calculated a
mean total percent quality for each study design category by dividing the mean total quality
points by the total quality points possible.
Results
A total of 14,407 article citations, 9,672 from Embase and 4,735 from PubMed, were initially
identified. After removing 851 non-unique citations (844 in both PubMed and Embase and 7
contained in Embase twice), 13,556 citations remained. With the addition of 371 articles iden-
tified through the reference lists of selected articles, the IARC publication [11], additional
PubMed searches, and the updated systematic search in PubMed, 13,927 records were
screened for eligibility of which 13,789 were excluded. One hundred thirty-eight full-text arti-
cles were abstracted and 80 were included (Fig 1).
We organized our review with summaries of the characteristics of included studies followed
by their results for pediatric cancer types using the International Classification of Childhood
Cancer third edition major diagnostic categories [14]. Within each major cancer type, results
are summarized by study design with overall associations generally reported first followed by
findings for specific abnormalities/subgroups.
Characteristics of studies included (Table 2)
Studies from 17 countries (Australia, Brazil Canada, China, Croatia, Denmark, France, Ger-
many, Hungary, Italy, the Netherlands, Norway, Sweden, Switzerland, Turkey, the United
Kingdom, and the United States) were published from 1958–2017. Study designs included 13
cohort, 58 case-control, 3 case-cohort, 3 nested case-control and 3 case series with external
comparison groups. BDs were measured through a variety of methods including interviews,
questionnaires, medical records, physical exams, administrative data linkages and from physi-
cian interview/report. Cancers were most commonly ascertained through hospital or popula-
tion-based tumor registries and death certificates.
Pediatric cancers overall (Table 3)
We identified 24 articles reporting findings for associations between pediatric cancer overall
and BDs.
Case-control studies (n = 12). Three studies reported ~2–4.5 fold increased odds of child-
hood cancer in association with any/BDs or major BDs [15–17], while one reported no associ-
ation [18]. For minor anomalies, four studies reported increased odds of varying magnitude
for minor anomalies overall (ORs = 4.25 and 44.6 [19, 20]), and specific minor anomalies (OR
>2-fold [21, 22]). One study reported positive associations ranging from 2.6–14.5 for a num-
ber of BD types [17]. Finally, four studies reported generally positive associations between rib
anomalies and childhood cancer with ORs ranging from 1.44 to 5.49 [23–26].
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Cohort studies (n = 12). Consistently elevated risks ranging from 1.8–3.05 were reported
for associations between any BDs/major BDs and pediatric cancers [27–35]. Increased cancer
risks were within the same range or lower when children with chromosomal anomalies were
excluded [32, 34–36]. One cohort study reported increased risks in children with different BD
types ranging from 1.69–15.52 with the exception of musculoskeletal abnormalities and limb
reduction defects [31]. Janitz et al. reported increased risks for CNS, eye/ear, cardiovascular,
orofacial, gastrointestinal, genitourinary, and musculoskeletal abnormalities with stronger
risks at younger ages (except orofacial where results were not reported) and when individuals
with chromosomal BDs were excluded [35]. Birthmarks (not including nevus simplex or pig-
mented nevi or cafe´-au-lait spots<3 cm or fewer than 6) were positively associated with
Fig 1. PRISMA flow diagram. The number of records screened is equal to the sum of the number of records initially identified in PubMed
and Embase after removing overalapping citations and the number of studies with citations identified through other sources shown in the
upper most right text box. After exclusions of non-relevant articles during the screening phase, 138 full-text text articles were abstracted, 58
of which were excluded leaving a total of 80 articles that were included in the review.
https://doi.org/10.1371/journal.pone.0181246.g001
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Table 2. Characteristics of included studies on the association between birth defects and childhood cancer.
Reference (location) BD ascertainment Pediatric cancer case ascertainment:
cancer types, age group, diagnosis
dates/years, case identification source
Comparison group ascertainment
Case-control studies
Stewart et al., 1958 [18]
(England and Wales)
Maternal interview Overall, 0–9 years, 1953–1955 (died of
cancer), Registrar General
Controls were selected from birth
registers matched to cases on age,
sex, and locality.
Ager et al., 1965 [39]
(Minnesota, U.S.)
Maternal interview/medical record
verification. The authors note that
“lesser conditions, such as nevi, were
not recorded”.
Leukemia, 0–4 years, 1953–1957 (died
of leukemia), Minnesota death
certificates
Two control groups were included
with a total of two controls per case. If
available, sex-matched sibling
controls were included with the
birthdate closest to the index child
and who had reached an age at the
time of interview that was the same or
older as the age of the index child
when they died. Neighborhood
controls were matched on sex and
birth date within one year.
Swerdlow et al., 1982 [91]
(United Kingdom)
The Oxford Survey of Childhood
Cancer and antenatal clinical notes
Testicular tumors, 0–15 years, 1953–73
(died of testicular cancer), the Oxford
Survey of Childhood Cancer
The comparison group was "all boys
who died during the same period from
malignant neoplasms other than of
genital site or of teratoma histology".
Wilkins et al., 1984 [77] (Ohio,
U.S.)
Ohio birth certificate files WT, NR, 1/1/1950-10/31/1981,
Columbus (Ohio) Children’s Hospital
Tumor Registry
Two controls per case were randomly
selected from birth certificate files
with one matched to the case on sex,
race, and birth year and the other
matched on these variables plus
mother’s county of residence.
Johnson et al., 1985 [66]
(Texas, U.S.)
The Texas State Department of
Health birth certificates. Both major
and minor BDs were included.
NB, 0–14 years, 1964–1978 (died of NB),
Texas death certificates
Two controls per case were randomly
selected from birth certificates
matched to cases on birth year.
Me´hes et al., 1985 [19]
(Switzerland)
Pediatric examination for minor BDs Overall, leukemia, solid tumors, 1.6–22
years, NR, Swiss University Children’s
Hospitals of Basel and Zurich Oncologic
Departments
Controls with infectious diseases
were matched 1:1 to cases on sex,
age, and ethnic origin. Siblings were
also examined where available.
Bunin et al., 1987 [78]
(Philadelphia, U.S.)
Parental interview WT, 0–14 years, 1970–1983, three
Philadelphia-area hospitals: Children’s
Hospital of Philadelphia,
St. Christopher’s Hospital for Children,
and Wilmington Medical Center
Controls were selected by RDD
matched to cases at a 1:1 ratio on
telephone area code and exchange,
birth year (within 3 years), and race.
Johnson et al., 1987 [62]
(Texas, U.S.)
The Texas State Department of
Health birth certificates
CNS, 0–14, deaths from 1964–1980,
Texas Department of Health death
certificates
Two controls per case were randomly
selected from Texas live births
frequency matched to cases on race,
sex, and birth year.
Neglia et al., 1988 [67]
(Minnesota, U.S.)
The Minnesota State Department of
Health birth certificates. The authors
note that BDs were coded by HICDA-
9.
NB, 0–8.9 years, cases born since 1969,
hospital review of NB cases seen in
Minnesota and bordering states
Four controls per case were selected
from live births in Minnesota matched
to cases on birth year.
Shu et al., 1988 [48]
(Shanghai, China)
Interview of parents, grandmothers,
and other relatives
Leukemia, 0–14 years, 7/1/1974-6/30/
1986, Shanghai Cancer Institute Tumor
Registry
Controls were selected from the
Shanghai general population at
random, matched to cases 2:1 on sex
and birth calendar year.
Baptiste et al., 1989 [55] (New
York State, U.S. (except New
York City, Westchester,
Rockland, Nassau, and Suffolk
counties)
Maternal interview CNS, 0–14 years, 1/1/1968-12/31/1977,
New York State Cancer Registry
Controls were randomly selected
from the New York State birth
certificate files matched to cases at a
2:1 ratio on birth year, sex, and race.
(Continued )
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Table 2. (Continued)
Reference (location) BD ascertainment Pediatric cancer case ascertainment:
cancer types, age group, diagnosis
dates/years, case identification source
Comparison group ascertainment
Birch et al., 1990 [56] (United
Kingdom)
Parental interview/medical record
verification (ICD-9 coded 740–759)
CNS, 0–14 years, 1980–1983 from
regional pediatric oncology centers, West
Midlands Regional Cancer Registry,
Manchester Children’s Tumor Registry,
Yorkshire Regional Cancer Registry
Two sets of controls were
ascertained from general practitioner
lists and hospitals matched to cases
on sex and age. The second set
excluded children with "a genetic or
other constitutional disease or
malformation known to be associated
with increased risk of cancer" and any
other major malformation or chronic
disease.
Magnani et al., 1990 [47] (Italy) Interview of parents/closest relatives ALL, AML, NHL, NR, 1974–1984,
Pediatric Hospital in Turin
Controls were a random sample of
children hospitalized at the same
hospital as cases.
Kajta´r et al., 1990 [79]
(Hungary)
Examinations of spine for vertebral
anomalies on i.v. pyelograms in cases
and X-rays in controls
WT, NR, NR, Department of Pediatrics,
University Medical School, Hungary
Controls were children with X-ray for
acute abdomen or trauma.
Zack et al., 1991 [40]
(Sweden)
The Swedish Medical Birth Registry
(ICD-8 codes 740–759)
All leukemias, lymphatic leukemias,
myeloid leukemias, other or unspecified
leukemias, 0–11 years, 1973–1984, the
Swedish National Cancer Registry and
Swedish Registry of Causes of Death
Five controls per case were selected
from the Swedish Medical Birth
Registry matched to cases on sex,
birth year and month.
Schumacher et al., 1992 [23]
(Germany)
Chest X-ray examination for rib
anomalies
Overall, yolk sac carcinoma, OS, HD,
histiocytosis X, NHL, ES, WT, STS, ALL,
brain tumor, NB, 9 months-21years, NR,
University Children’s Hospital,
Langenbecksrasse
Chest roentgenograms from patients
without cancer with a similar age
distribution as cases (15 months-14
years) were reviewed for comparison.




Overall, ALL, other leukemia, HL, other
lymphomas, CNS, STS, bone tumors,
WT, NB, RB, HB, GCT, epithelial tumors,
Other neoplasms, 0–14 years, 1980–
1983, regional pediatric oncology
centers, West Midlands Regional Cancer
Registry, Manchester Children’s Tumor
Registry, Yorkshire Regional Cancer
Registry
Two sets of controls were selected
from general practitioner lists and
hospitals matched to cases on sex
and age. The second set excluded
children with "a genetic or other
constitutional disease or
malformation known to be associated
with increased risk of cancer" and any
other major malformation or chronic
disease.
Savitz et al., 1994 [15] (U.S.) Maternal interview or alternate
respondent. BDs were recorded
verbatim and blindly classified as
major, minor, or not a defect.
Overall, ALL, brain, lymphoma, STS,
0–14 years, 1/1/1976-12/31/1983,
primary data sources were the Colorado
Central Cancer Registry and the
Colorado Department of Health [106]
Controls were selected through RDD
and frequency matching on location,
sex, and age within 3 years.
Cordier et al., 1994 [61] (Ile de
France, France)
Maternal interview. The authors noted
excluding "minor anomalies such as
nevi or birthmarks".
Brain, 0–15 years, 7/1/1985-6/30/1987,
medical record abstractions from the
neurosurgery, neurology, pediatric,
pediatric oncology, or radiology
departments at 13 hospitals
Controls were selected from the
general population through sampling
households on a representative list
provided by the census bureau and
telephone books at random matched
to cases on birth year.
Gold et al., 1994 [64] (U.S.) Parental interview Brain, 0–17 years, 1/1/1977-12/31/1981
from eight Surveillance, Epidemiology,
and End Results tumor registries
Three controls per case were
identified through a variety of
methods including RDD, lists of non-
institutionalized individuals
maintained by the Hawaii Department
of Health and through a random
sample of households (Pierce
County, Washington). Controls were
individually matched to cases on age,
sex, and mother’s racial/ethnic
classification.
(Continued )
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Table 2. (Continued)
Reference (location) BD ascertainment Pediatric cancer case ascertainment:
cancer types, age group, diagnosis
dates/years, case identification source
Comparison group ascertainment
McCredie et al., 1994 [65]
(Australia)
Maternal interview Brain, 0–14 years, 1985–1989, New
South Wales Central Cancer Registry
Two controls per case matched on
sex and age were ascertained from
eligible women on the Electoral Roll.
Yang et al., 1995 [86] (U.S.) Parental interview. BDs were
classified as major and minor.
RMS, 0–20 years, 4/1982-7/1988,
Intergroup RMS study of the Children’s
Cancer Group and the Pediatric
Oncology Group
Controls were ascertained by RDD
matched to cases on telephone area
code and exchange, sex, age, and
race.
Shu et al., 1995 [89] (U.S.,
Canada, Australia)
Self-administered questionnaire Malignant GCT, 0–14 years, 1982–1989,
Children’s Cancer Group
Controls were ascertained by RDD as
part of the CCG-E04 pool.
Cnattingius et al., 1995 [49]
(Sweden)
Swedish Medical Birth Register (ICD-
8 to 1986 and ICD-9 after).
Registration was completed upon
mother and child leaving the hospital.
Lymphatic leukemia, 0–14 years who
were born between 1973 and 1989,
diagnoses through 1989, National
Cancer Register
Five controls per case were selected
from the source population who were
alive at the case diagnosis and who
were matched on sex, birth year and
month.
Cnattingius et al., 1995 [41]
(Sweden)
Swedish Medical Birth Register
(ICD-8 to 1986 and ICD-9 after).
Registration completed when mother
and child leave the hospital.
Myeloid leukemia, 0–14 years who were
born between 1973 and 1989, diagnoses
through 1989, National Cancer Register
Same as Cnattingius et al., 1995 [49]
Adami et al., 1996 [54]
(Sweden)
Swedish Medical Birth Register (ICD-
8 to 1986 and ICD-9 after).
NHL, 0–14 years who were born between
1973 and 1989, diagnoses through 1989,
the National Cancer Register
Same as Cnattingius et al., 1995 [49]
Gelberg et al., 1997 [12] (New
York State, U.S., excluding
New York City)
Telephone interview with the subject
and/or parents, birth certificates and
school and medical records
OS, 0–24 years, 1978–1988, the New
York State Cancer Registry
Controls were ascertained from New
York live birth records and matched
to cases at a 1:1 ratio on birth year
and sex.
Altmann et al., 1998 [17]
(Victoria Australia)
The Victorian Perinatal Data
Collection Unit Congenital
Malformations/BDs Register (BDs
coded according to the British
Pediatric Association’s modification of
the ICD-9). The authors noted that
"the register collects information on
both structural defects and
chromosomal anomalies at
birth. . .The register excludes certain
trivial malformations, such as birth
marks, skin tags and hydroceles."
BDs were ascertained up to the age of
15 years.
Overall, leukemia (ALL, AML), CNS
(astrocytoma), SNS (NB), lymphoma,
STS (RMS), renal (WT), RB, germ cell/
gonadal, bone, and hepatic, 0–14 years,
1/1/1984 to 12/31/1993, the Victorian
Cancer Registrar
Four live born controls per who
survived the neonatal period were
selected from Victorian births at
random and matched to cases on
date of birth within 6 months.
Me´hes et al., 1998 [52]
(Germany)
Physical exam for mild errors of
morphogenesis
Leukemia, 7 months-14 years, NR, the
Department of Pediatrics, University
Medical School of Pe´cs and the
University Children’s Hospital, Tu¨bingen,
Germany
There were two control comparison
groups: 1) children with acute
infectious diseases and 2) siblings.
Mertens et al., 1998 [43] (U.S.,
Canada, Western Australia)
Maternal interview (ICD-9 coded 740–
759). Some minor BDs were included.
ALL, AML, cases from three different
leukemia studies diagnosed at 0–18
months (CCG-E09), 0–17 years
(CCG-E14), 0–14 years, 1983–1994
(CCG-E15), the Children’s Cancer Group
Controls were selected from regional
populations by a modified RDD
method and matched on telephone
exchange, age, and race (for E14 and
E15).
Buck et al., 2001 [68] (New
York State, U.S., excluding
New York City)
Parental telephone interview/
supplemented with data from birth
certificates
NB, 0–5 years, 1976–1987, the New York
State Cancer Registry
Controls were randomly selected
from live birth registries and
frequency matched to cases on birth
year.
(Continued )
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Table 2. (Continued)
Reference (location) BD ascertainment Pediatric cancer case ascertainment:
cancer types, age group, diagnosis
dates/years, case identification source
Comparison group ascertainment
Infante-Rivard et al., 2001 [42]
(Que´bec, Canada)
Parental interview for major BDs
(ICD-9 coded 751–754)
ALL, 0–9 years, 1980–1993,
Government-sanctioned tertiary care
centers
Controls were selected from family
allowance files and were individually
matched to cases on age within 3
months, sex, and region of residence
at diagnosis.
Roganovic et al., 2002 [50]
(Rijeka, Croatia)
NR (minor BDs ascertained) Hematologic, 5 months-16 years, 1983–
1997, the Division of Hematology,
Department of Pediatrics, University of
Rijeka
Controls were healthy children that
were the same age and gender as
cases.
Me´hes et al., 2003 [80] (Pe´cs,
Hungary)
Abdominal roentgenograms and
anteroposterior radiographs for cases;
radiography for trauma or acute
abdomen in controls; physical exam
for both cases and controls. Spinal
dysraphism ascertained.
WT, 2 months to 9 years for cases, NR,
Department of Pediatrics, University
Medical School of Pe´cs, Pe´cs, Hungary
Controls were children with
radiography for trauma or acute
abdomen ranging in age from 1–10
years.
Menegaux et al., 2005 [71] (U.
S. and Canada)
Maternal interview (ICD-9 coded 740–
759, both major and minor BDs were
ascertained).
NB, 0–18 years, 1992–1994, the
Children’s Oncology Group
One control per case was selected by
RDD individually matched to cases
on date of birth within 6 months for
cases aged <3 years and 1 year for
cases aged >3 years.
Merks et al., 2005 [26] (The
Netherlands)
Review of chest radiographs for rib
anomalies
Overall, NB, GCT, RMS, WT, OS, ES,
MB, AST, HD, AML, ALL, NHL, Other
malignancies, 0–18 years, 1/1/1998-12/
31/2002, Late Effects of Childhood
Cancer Clinic and the Emma Children’s
Hospital, Academic Medical Center for
newly diagnosed patients
Controls aged 0–18 years were
selected from patient chest
radiographs ordered by general
practitioners and pediatricians in the
outpatient ward and emergency room
physicians.
Podvin et al., 2006 [44]
(Washington State, U.S.)
Birth records Leukemia, 0–19 years, 1981–2003,
Washington State Cancer Registry and
the Cancer Surveillance System of
Western Washington
Ten controls without leukemia per
case were randomly selected from
the birth certificate records and were
frequency matched to cases on birth
year.
Urayama et al., 2006 [73]
(California, U.S.)
Birth certificates NB, 0–4 years, 1988–1997, California’s
statewide cancer registry
Two controls per case were randomly
selected from birth certificates
matched to cases on birth date and
gender. Controls were replaced if
they died younger than their matched
case’s diagnosis age.
Chow et al., 2007 [70]
(Washington, U.S.)
Birth certificates (ICD-9 codes 740–
759, major and minor BDs
ascertained). For individuals who
were born1987 additional ICD-9
codes for discharges were obtained
through linkage of birth certificates to
the Comprehensive Hospital Abstract
Reporting System.
NB, <20 years, 1993–2004, Washington
State Cancer Registry & Cancer
Surveillance System (CSS) of Western
Washington
Ten controls without NB per case
were randomly ascertained and were
frequency matched on year of
delivery.
Munzer et al., 2007 [69]
(France)
Maternal telephone interview (ICD-10
coded Q00-Q99). BDs were classified
as minor and major according to the
European Surveillance of Congenital
Anomalies.
NB, 0–14 years, 1/1/2003-12/31/2004,
the National Registry of Hematological
Cancer and the National Registry of
Childhood Solid Tumors
Controls were randomly selected
using phone numbers representative
of the French population frequency
matched to cases on age and gender.
Loder et al., 2007 [25]
(Indiana, U.S.)
Chest radiographs were reviewed for
rib number.
Overall, solid, lymphoproliferative, and
neural, 1–12 years, malignancies cared
for from 2001–2005, Riley’s Children’s
Hospital Pediatric Tumor Registry
A similar sized control group
identified from the Radiology
Department logs was selected from
children admitted at the same
hospital for polytrauma.
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Table 2. (Continued)
Reference (location) BD ascertainment Pediatric cancer case ascertainment:
cancer types, age group, diagnosis
dates/years, case identification source
Comparison group ascertainment
Mallol-Mesnard et al., 2008
[58] (France)
Maternal interview. BDs were
classified as minor and major
according to the European
Surveillance of Congenital Anomalies.
CNS, 0–14 years, 1/1/2003-12/31/2004,
National Registry of Childhood
Haematological Cancers and the
National Registry of Childhood Solid
Tumors
Controls were selected from the
French population by sampling from
60,000 representative addresses
taken from the French national
telephone directory plus unlisted
phone numbers generated randomly.
Age and gender quotas were applied.
Merks et al., 2008 [21]
(Amsterdam, Netherlands)
Clinical examination by a physician for
major and minor anomalies. BD
classification was based on Merks JH
et al., 2003 [107].
Overall, 0–18 years, 1/2000-3/2003,
Clinic for Late Effects of Childhood
Cancer Clinic in the Emma Children’s
Hospital, Academic Medical Center
Controls were recruited from the city
of Haarlem and the surrounding
semirural and rural area.
Johnson et al., 2009 [88] (U.S.
and Canada)
Maternal interview GCT, 0–14 years, 1/1/1993-12/31/2001,
the Children’s Oncology Group
The control group was recruited
through RDD and frequency was
matched to cases on sex and birth
year within 1 year at ratios of
approximately 1:2 for males and 1:1
for females.
Johnson et al., 2010 [46] (U.S.
and Canada)
Maternal interview. Both major and
minor BDs were ascertained.
All infant leukemia, ALL, AML, 0–1 year,
1/1/96-10/13/02 (Phase I) 1/1/03-12/31/
06 (Phase II), the Children’s Oncology
Group
Phase one controls (5/1999-10/2002)
were sampled from the population
through RDD. Phase two controls
(10/2003-3/2008) were selected from
state birth registries. Controls were
frequency matched to cases on birth
year and region of residence based
on the phase one case distribution.
Durmaz et al., 2011 [20]
(Turkey)
Two medical geneticists qualified in
pediatric genetic dysmorphology
examined patients for age-
independent minor BDs by using the
London Dysmorphology database.
Overall, hematopoetic, CNS, WT/GCT,
RMS, OS, NR, NR, Cases were
diagnosed at Ege University Faculty of
Medicine, Izmir, Turkey
The control group was randomly
recruited from the Pediatric
Outpatient Service at the Ege
University Medical Faculty.
Partap et al., 2011 [57]
(California, U.S.)
California Office of Vital Records’ birth
certificate database
CNS, LGG, HGG, MB, PNET, GCT,
EPD, 0–14 years, 1988–2006, California
Cancer Registry
Four controls that matched to each
case on birth date and sex were
selected from the California birth
certificate database.
Citak et al., 2011 [22] (Turkey) Two pediatric hematologists/
oncologists examined patients for
minor BDs using the London
Dysmorphology database
ALL, AML, chronic myelocytic leukemia,
chronic myelomonocytic leukemia, MDS,
1.5–18 years, NR, cases diagnosed at a
single institution
The control group consisted of
healthy children of the same age,
gender, and ethnicity.
Zierhut et al., 2011 [24]
(Minnesota, U.S.)
Radiologists’ X-Ray examination for
rib anomalies
Overall, all acute leukemia, ALL, AML,
lymphoma, CNS, NB, renal, bone tumors,
sarcomas, 0–19 years, 2003–2009, the
University of Minnesota Medical Center-
Fairview
Controls were randomly selected
pediatric patients who received a
chest X-ray at Fairview Ridges
Hospital in Burnsville, MN.
Rudant et al., 2013 [45]
(France)
Maternal interview with structured
questionnaires. BDs were classified
as major and minor according to the
European Surveillance of Congenital
Anomalies.
All acute leukemia, ALL, AML, 0–14
years, 2003–2004, the National Registry
of Childhood Hematopoietic
Malignancies
Controls were recruited at random
from the telephone directory using
gender and age quotas in eight strata
reflecting the expected distribution of
all the cases.
Citak et al., 2013 [22] (Turkey) Two pediatric hematologists/
oncologists examined patients for
minor BDs using the London
Dysmorphology Database.
Overall, lymphoma, solid tumors, 0.1–18
years, NR, "2 different institutions"
Controls were selected from
individuals seen at the healthy child
clinic of Mersin University Hospital
and Mersin Obstetric, Gynecology
and Children Hospital, Department of
Pediatric Hematology and Oncology
who were within the same age range,
sex, and ethnicity as cases.
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Table 2. (Continued)
Reference (location) BD ascertainment Pediatric cancer case ascertainment:
cancer types, age group, diagnosis
dates/years, case identification source
Comparison group ascertainment
Parodi et al., 2014 [72] (Italy) Parental interview, structured
questionnaire (ICD-9 coded 740–759)
NB, 0–10 years, 1998–2001, Pediatric
Oncology Centers of the Italian
Association of Pediatric Hematology and
Oncology (AIEOP)
Controls were randomly selected
from the National Health Service
database matched on gender, date of
birth and area of residence.
Venkatramani et al., 2014 [84]
(U.S.)
Maternal interview/ the Utah
Population Database (UPDB, ICD-9
codes 740–759)
HB, 0–5 years, 2000–2008, the
Children’s Oncology Group (COG) for the
discovery cohort, the UPDB linked to the
State Cancer Registry from 1978–2010
for the validation cohort
The discovery control group was
identified from the birth registries
from 32 states and matched to cases
on birth weight, gender, birth year,
and region. The validation control
group was selected randomly from
the Utah population and matched
10:1 to cases on gender and birth
year.
Greenop et al., 2014 [60]
(Australia)
Mailed exposure questionnaire Brain tumors, NR (childhood), 2005–
2010, 10 Australian oncology centers
Controls were recruited through
random digit dialing and matched to
childhood CBT cases on age, sex,
and state of residence at a 3:1 ratio
[108].
Santos et al., 2016 [109]
(Brazil)
Exam for cafe´-au-lait spots by two
trained dysmorphologists
Solid tumors (clear cell renal cell
carcinoma, CNS, EWS, fibrosarcoma,
GCT, HB, OS, RB, RMS, synovial
sarcoma, STS, WT), 0–18, NR, NR
Cases were from Rio De Janeiro and
Sao Paulo. The control group was
comprised of school children from Rio
de Janeiro without a diagnosis of
cancer or a predisposing syndrome.
Rios et al., 2016 [74] (France) Maternal telephone interview (ICD-10
coded). Minor BDs or unspecified BDs
were excluded according to the
European Surveillance of Congenital
Anomalies.
NB, <6 years, 2003–2004 (ESCALE) and
2010–2011 (ESTELLE), French National
Registry of Childhood Cancer
The analysis was based on pooled
data from two French case-control
studies (ESTELLE and ESCALE).
Controls were frequency matched to
cases on sex and age so that there
would be at least one control per
case.
Hall et al.c, 2017 [90]
(California, U.S.)
California birth certificates GCT, yolk sac tumors, teratomas,5
years, 1988–2013, California Cancer
Registry
Controls were randomly selected
from California birth records
frequency matched to cases on birth
year.
Bailey et al., 2017 [59]
(France)
Maternal telephone interview Brain tumors, 0–14 years, 2003–2004
(ESCALE) and 2010–2011 (ESTELLE),
French National Registry of Childhood
Cancer
Same as Rios et al., 2016 [74].
Cohort studies
Windham et al., 1985 [27]
(Norway)
Medical Birth Registry (ICD-8 codes
740–759)
Overall, leukemia, nervous system
tumors, renal cancer, eye cancer, NB,
0–13 years, 1967–1980, the Norwegian
Cancer Registry
Individuals without BDs from the
Norwegian Medical Birth Registry
comprised the unexposed group.
Mili et al., 1993 [28] (Georgia,
U.S.)
The Metropolitan Atlanta Congenital
Defects Program (major BDs, six-digit
code for reportable BDs, a
modification of the British Pediatric
Association Code, which uses a
modification of ICD-9 codes). BDs
were captured in the first year of life.
Overall, leukemia, brain tumors, NB, WT,
RB, 0–14, 1/1/1975-12/31/1988, the
Georgia Center for Cancer Statistics at
Emory University
The expected number of cancer
cases was calculated based on
Atlanta Surveillance Epidemiology
and End Results rates.
Mili et al., 1993 [29] (Iowa, U.
S.)
The Iowa Birth Defects Registry (only
major BDs, six-digit code for
reportable BDs, a modification of the
British Pediatric Association Code,
which uses a modification of ICD-9
codes). BDs were captured in the first
year of life.
Overall, leukemia, brain tumors, NB,
sarcoma, 0–7 years, 1/1/1983-12/31/
1989, the State Health Registry of Iowa’s
Cancer Registry (a SEER registry)
The expected number of cancer
cases was calculated based on Iowa
Surveillance Epidemiology and End
Results rates.
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Reference (location) BD ascertainment Pediatric cancer case ascertainment:
cancer types, age group, diagnosis
dates/years, case identification source
Comparison group ascertainment
Agha et al., 2005 [33] (Ontario,
Canada)
Canadian Congenital Anomalies
Surveillance System (ICD-9 codes
740.0–759.9). BDs were captured in
the first year of life.
Overall, leukemia, lymphoma, CNS,
sympathetic nervous system, RB, renal
tumors, bone tumors, STS, GCT,
trophoblastic and other gonadal
carcinoma, and malignant epithelial,
0–19 years, 1979–1996, the Ontario
Cancer Registry
Children without BDs were selected
from the Birth Certificate File of
Ontario. For every child with a BD,
one child without BDs was selected
matched on birth year, maternal age,
birth order, mother’s marital status,
and parent’s place of birth (Ontario
vs. other).
Johnson et al., 2007 [37] (U.S.) Both maternal interview using
standardized tools and medical
examinations of the children for
birthmarks
Overall, 0–8 years, 1959–1966, the
Collaborative Perinatal Project (CPP)
subject population
Children without birthmarks in the
CPP cohort were used as the
comparison group.
Bjørge et al., 2008 [75]
(Norway)
The Medical Birth Registry of Norway NB, 0–14 years, 1967–2004, the Cancer
Registry of Norway
The comparison group included all
live born children in Norway during
1967–2004 without reported
congenital malformations.




Survey (ICD-10 coded BDs). The
authors note including only "major
congenital anomaly subtypes" BDs
were captured in the first year of life.
Overall, ALL, AML, other leukemia, HL
and NHL, brain, NB, WT, RB, RMS, and
others, NR, 1985–2001, the Northern
Region Young Persons Malignant
Disease Registry
Children without BDs born in the
Northern Region were used as the
comparison group.
Carozza et al., 2012 [31]
(Texas, U.S.)
Texas Birth Defects Registry (1979
British Pediatric Association
Classification of Diseases and the
1979 ICD-9-CM, as modified by the U.
S. CDC and the Texas Department of
State Health Services). Major
structural and chromosomal BDs were
included. More minor defects were
included if the individual also had a
major BD. BDs were captured in the
first year of life.
Overall, leukemia, lymphoma, CNS, NB,
RB, renal tumors, hepatic tumors,
malignant bone tumors, STS, GCT, other
epithelial, 0–14 years, 1996–2005, the
Texas Cancer Registry
All children live born in Texas and not
registered in the Texas Birth Defects
Registry who were identified through
birth certificates were included as the
controls.
Fisher et al., 2012 [36]
(California, U.S.)
The California Birth Defects
Monitoring Program and birth
certificates (major BDs were classified
based on the British Pediatric
Association Classification of Diseases
codes, as modified by the CDC). BDs
were captured in the first year of life.
Overall, leukemia, lymphoma, CNS, NB,
WT, Non-CNS germ cell, RMS, 0–14
years, 1988–2006, the California Cancer
Registry
Children without major BDs born from
1988–2004 were used as the
comparison group.
Botto et al., 2013 [32] (Utah,
Arizona, Iowa, U.S.)
State Birth Defect Surveillance
Program (selected major BDs as
defined by the National Birth Defect
Prevention Network); BD’s were
captured up to 15 years of age.
Overall, leukemia, MDS/MPD,
lymphoma, brain tumor, NB spectrum,
RB, kidney tumor, liver tumor, sarcoma,
germ cell, trophoblastic and gonadal
tumor, 0–14 years, 1968–2005 for AZ,
1983–2005 for IA, 1994–2008 for Utah,
Arizona and Utah state cancer registries
The comparison group included
individuals without BDs selected
randomly from state birth certificates
who were frequency matched 3:1 to
the cases by birth year.
Sun et al., 2014 [38]
(Denmark)
Danish National Hospital Register
(Danish version of ICD-8 codes from
1977–1993: 740–743, 746–747, 759,
ICD-10 codes from 1994 onwards
Q00-07, Q20-28, Q90-99)
Overall, CNS, mesothelial and soft
tissue, skin, lymphatic and
haematopoietic, other systems, 0–19
years, 1/1/1977-12/31/2007, Danish
Cancer Registry
The comparison group consisted of
all children without BDs live born in
Denmark between 1977–2007 after
excluding missing data, adopted
children, twins, and chromosomal
anomalies.
Dawson et al., 2015 [34]
(Western Australia)
Western Australian Register of
Development Anomalies (British
Pediatric Association Classification of
Diseases, a five-digit extension of
ICD-9). BDs were captured in the first
year of life.
Overall, leukemia, lymphoma, CNS, NB,
RB, renal tumors, hepatic, bone, STS,
gonadal and germ cell, other epithelia/
melanoma, >90 days-14 years, 1982–
2007, Western Australia Cancer Registry
The comparison group included all
live born children with > 90 days of
follow-up born in Western Australia
from 1982–2007 BDs.
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childhood cancers (HRs 2.81 and 2.03 for those diagnosed at 0–8 and 1–8 years respectively)
[37]. Botto et al. examined a number of specific BD types in children without chromosomal
anomalies observing that a majority increased risk [32]. Finally, Sun et al. reported BDs of
both the circulatory and nervous system were positively associated with pediatric cancer with
Table 2. (Continued)
Reference (location) BD ascertainment Pediatric cancer case ascertainment:
cancer types, age group, diagnosis
dates/years, case identification source
Comparison group ascertainment
Janitz et al., 2016 [35]
(Oklahoma, U.S.)
Oklahoma Birth Defects Registry (as
defined by the CDC British Pediatric
Association codes for congenital
anomaly categories and classified
according to the National Birth
Defects Prevention Network (2004)).
BDs were reported up to age 6 years
but signs/symptoms must have been
present by age 2 years.
Overall, leukemia, lymphoma, CNS,
hepatic tumors, STS, GCT, 0–12 years,
1/1/1997-3/31/2009, Oklahoma Central
Cancer Registry
The comparison group comprised all
singleton births in Oklahoma from 1/
1/1997 to 3/31/2009 who were not
linked to the Oklahoma Birth Defects
Registry.
Case-cohort studies
Johnson et al., 2008 [76]
(Minnesota, U.S.)
Minnesota Birth Registry records NB, 28 days-14 years, 1988–2004,
Minnesota Cancer Surveillance System
The sub-cohort was comprised of
four individuals per childhood cancer
case randomly matched to cases on
birth year who were born from 1976–
2004.
Puumala et al., 2008 [82]
(Minnesota, U.S.)
Minnesota Birth Registry records WT, 28 days-14 years, 1988–2004,
Minnesota Cancer Surveillance System
Same as Johnson et al., 2008 [76]
Spector et al., 2008 [85]
(Minnesota, U.S.)
Minnesota Birth Registry records HB, 28 days-14 years, 1988–2004,
Minnesota Cancer Surveillance System
Same as Johnson et al., 2008 [76]
Nested case-control studies
Wanderas et al., 1998 [92]
(Norway)
Medical Birth Registry (ICD-8 codes
and classifications by the Medical
Birth Registry and Statistics Norway).
The authors indicate BDs of "all types"
were included (Table 2). Recorded
“presentation anomalies” (present at
birth).
Testicular GCTs, 0–28 years, 1967 to
June 1996, Norwegian Cancer Registry
Approximately 100 controls per case
were obtained from the Norwegian
Birth Registry for the birth period of
1967–1995.
Lindblad et al., 1992 [81]
(Sweden)
Swedish Medical Birth Registry. BDs
captured up to one month of age.
WT, 0–11 years, 1973–1984, Swedish
National Cancer Registry
Five sex and birth month and year
matched controls without cancers
were selected for each case from the
Medical Birth Register.
Linet et al., 1996 [63]
(Sweden)
The National Medical Birth Register
(ICD-8 codes 740–759)
Brain tumors, 0–17 years, 1973–1989,
the National Cancer and Death Registers
Same as Lindblad et al., 1992 [81]
Case series studies with external comparison groups
Breslow et al., 1982 [83] (The
National Wilms’ Tumor Study
(NWTS))[110]
The NWTS registration form (ICD-9
codes 741–759)
WT, 0–15 years, 10/1969–3/1981, the
NWTS Statistical Center; histologic
confirmation was available for 75% of the
patients
Survey findings were compared to
the CPP and results from the CDC
Surveillance system on BDs.
Ruymann et al., 1988 [87]
(Ohio, U.S.)
Autopsy reports (major and minor
ascertained)
RMS, NR, NR, Autopsy results from
children in the Intergroup
Rhabdomyosarcoma Studies I and II
Rates were compared with those
from the NWTS and the CPP.
Narod et al., 1997 [53] (United
Kingdom)
A postal questionnaire to family
physicians of children diagnosed with
cancer and who were alive at the end
of 1988 (ICD-9 codes 7400–7599)
Leukemia, lymphoma, brain and spinal
cord, NB, RB, WT, liver, OS, ES, STS,
gonadal and germ cell, 0–14 years,
1971–1986, National Registry of
Childhood Tumors
The expected number of cancer
cases was calculated based on two
groups: 1) the frequency of BDs
among children in the study group,
and 2) the frequency of BDs recorded
in the British Columbia Health
Surveillance Registry (BC Registry).
https://doi.org/10.1371/journal.pone.0181246.t002
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1,416 (25) 1,416 (25) Overall Any BD 1.0 (0.57–1.75)a,b BDs excluding DS and naevi.
Me´hes et al.,
1985 [19]
104 (72) 104 (36) Overall Minor 4.25 (2.38–7.59)a,b
Schumacher et
al., 1992 [23]
1,000 (242) 200 (11) Overall Rib 5.49 (2.94–10.25)a,b
1,000 (22) 200 (1) Overall Cervical rib left 4.48 (0.60–33.40)a,b
1,000 (21) 200 (1) Overall Cervical rib right 4.27 (0.57–31.92)a,b
1,000 (161) 200 (7) Overall Cervical rib bilateral 5.29 (2.44–11.46)a,b
1,000 (5) 200 (0) Overall Synostoses ND
1,000 (12) 200 (1) Overall Aplasia/hypo- 2.42 (0.31–18.69)a,b
1,000 (21) 200 (1) Overall Bifurcation 4.27 (0.57–31.92)a,b
Mann et al.,
1993 [16]




242 (21) 212 (11) Overall Major BD 2.1 (0.9–5.0)b Estimate adjusted for diagnosis year.
Altmann et al.,
1998 [17]
570 (55) 2,280 (58) Overall Any BD 4.5 (3.1–6.7)b Adjusted for 6-month calendar period,
gender, birth weight, gestational age,
and maternal age.
570 (18) 2,280 (5) Overall Chromosomal (758) 16.7 (6.1–45.3)b
570 (6) 2,280 (3) Overall Chromosomal excluding
DS (758)
9.2 (2.3–37.3)b
570 (5) 2,280 (3) Overall Nervous system (740–
742, 340–2, 344, 350–9)
6.5 (1.5–27.8)b
570 (8) 2,280 (4) Overall Cardiac septal/bulbous
cords (745)
8.6 (2.6–29.0)b
570 (3) 2,280 (4) Overall Ventricular septal defect
(745.40–49)
4.4 (0.9–22.3)b
570 (4) 2,280 (4) Overall Ventricular septal defect
excluding DS (745.40–49)
4.1 (1.0–16.8)b
570 (9) 2,280 (7) Overall Other heart/circulatory
system (746–747)
5.5 (2.0–15.0)b
570 (6) 2,280 (7) Overall Other heart circulatory
excluding DS (746–747)
3.6 (1.2–10.8)b
570 (3) 2,280 (1) Overall Respiratory system (748) 14.5 (1.5–142)b
570 (5) 2,280 (3) Overall Eye/face/neck (743, 744) 7.3 (1.7–30.9)b
570 (7) 2,280 (11) Overall Gastrointestinal system
(750,751)
3.3 (1.2–9.0)b
570 (13) 2,280 (22) Overall Musculoskeletal system
(754–756)
2.7 (1.3–5.4)b
570 (4) 2,280 (5) Overall Congenital dislocation of
hip (754.30)
3.2 (0.9–12.5)b
570 (6) 2,280 (9) Overall Genitourinary system
(752–753)
2.9 (1.0–8.1)b
570 (3) 2,280 (5) Overall Hypospadias (752.60) 2.6 (0.6–10.9)b
570 (2) 2,280 (1) Overall Endocrine/metabolic
(240–279)
8.4 (0.8–93.2)b





906 (78) 881 (54) Overall Cervical rib 1.44 (1.01–2.07)a,b
906 (48) 881 (58) Overall Aplasia 12th ribs 0.79 (0.54–1.18)a,b
906 (8) 881 (8) Overall Lumbar ribs 0.97 (0.36–2.60)a,b
906 (5) 881 (6) Overall Bifurcation 0.81 (0.25–2.66)a,b
906 (2) 881 (3) Overall Synostosis-Bridging 0.65 (0.11–3.88)a,b
906 (1) 881 (0) Overall Segmentation ND
Loder et al.,
2007 [25]
218 (39) 200 (16) Overall Abnormal rib number
(normal = 24 ribs)
2.5 (1.4–4.6)b Children with a known BD or DS were
excluded.
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903 (65) 923 (6) Overall Blepharophimosis 11.1 (4.8–25.4)b Cases and controls were examined by
two different observers. Although the
authors report that "11% of controls and
7% of patients were scored
independently by 2 observers, resulting
in high scores", they do not report the
data associated with this comment.
903 (58) 923 (2) Overall Asymmetric lower limbs 29.6 (7.3–121.0)b
903 (30) 923 (3) Overall Sydney crease 10.2 (3.1–33.4)b
903 (26) 923 (3) Overall Broad foot 8.9 (2.7–29.2)b
903 (14) 923 (0) Overall Isolated short metatarsals 1 (1.8-1)b
903 (13) 923 (0) Overall Short distal phalanx of
thumb
1 (1.6-1)b
903 (18) 923 (2) Overall Port-wine stain (Major
anomaly)
9.2 (2.1–39.5)b
903 (12) 923 (0) Overall Hyperconvex nails 1 (1.5-1)b
903 (43) 923 (16) Overall Retrognathia 2.8 (1.6–4.8)b
903 (25) 923 (6) Overall Hypoplastic alae nasi 4.3 (1.8–10.3)b
903 (52) 923 (24) Overall Prominent ears 2.2 (1.4–3.6)b
903 (15) 923 (2) Overall Broad hand 7.7 (1.8–33.4)b
903 (32) 923 (12) Overall Scoliosis 2.7 (1.4–5.3)b
903 (51) 923 (26) Overall Hypertelorism 2.0 (1.3–3.2)b
903 (15) 923 (3) Overall Tall stature 5.1 (1.5–17.6)b
903 (18) 923 (3) Overall Microcephaly 6.1 (1.8–20.8)b
903 (13) 923 (3) Overall Macrocephaly 4.4 (1.3–15.5)b
Durmaz et al.,
2011 [20]
200 (192a) 200 (70a) Overall Any minor 44.6 (20.7–95.7)a,b
Zierhut et al.,
2011 [24]
455 (31) 1,133 (51) Overall Any rib 1.60 (1.00–2.65)b Estimates adjusted for sex and age.
455 (29) 1,133 (47) Overall Rib number (<24 or >24) 1.66 (1.00–2.74)b
455 (6) 1,133 (9) Overall Cervical ribs 1.63 (0.55–4.80)b
Citak et al., 2013
[22]
116 (24) 116 (6) Overall Eye 4.78 (1.88–12.20)b Minor anomalies for major sites are
presented; includes only patients with
lymphoma and solid tumors.
116 (46) 116 (7) Overall Ear 10.23 (4.37–23.94)b
116 (75) 116 (21) Overall Mouth 8.28 (4.51–15.18)b
116 (35) 116 (5) Overall Hand 9.59 (3.60–25.56)b




42 (22,856) NA Overall Any BD 1.9 (1.4–2.5)c* Did not exclude any known genetic
syndromes. Estimates are age
standardized.
NR (NR) NA Overall Any BD (Male) 1.7c*
NR (NR) NA Overall Any BD (Female) 2.1c*
NR (NR) NA Overall (0–4 years) Any BD (Male) 1.5c
NR (NR) NA Overall (0–4 years) Any BD (Female) 2.4c*
NR (NR) NA Overall (5–9 years) Any BD (Male) 2.7c*
NR (NR) NA Overall (5–9 years) Any BD (Female) 1.5c
Mili et al., 1993
[28]
31 (19,373) 400 (524,931) Overall Any BD 2.2 (1.5–3.2)d Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.
Mili et al., 1993
[29]
16 (10,891) 290 (241,473) Overall Any BD 2.0 (1.2–3.3)d Did not exclude any known genetic
syndromes. Estimates adjusted for age
and sex. The authors note that "by age
5 years, the risk of cancer for children
with BDs was 2.0 times the risk for the
general population; by age 8 years, the
risk of cancer for children with BDs was




139 (45,200) 73 (45,200) Overall Any BD 2.0 (1.8–2.4)c Did not exclude any known genetic
syndromes.33 (NR) 6 (NR) Overall (<1 year) Any BD 5.8 (3.7–9.1)c
(Continued)
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5 (NR) 40 (NR) Overall (0–8 years) Birthmarks 2.81 (1.11–7.13)e Individuals with suspected birthmarks
were excluded. The authors note that
none of the individuals were recorded
as having a genetic syndrome.
3 33 (NR) Overall (1–8 years) Birthmarks 2.03 (0.62–6.62)e
Rankin et al.,
2008 [30]
39 (NR) 812a (NR) Overall Any BD 2.86 (2.11–3.89)f;
1.8 (1.2–2.7)f DS
excluded






Overall Any BD 3.05 (2.65–3.50)f Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
17 (115,686) NR (3,071,255a) Overall CNS 3.61 (2.10–5.79)f
4 (115,686) NR (3,071,255a) Overall Neural tube 3.03 (0.83–7.78)f
6 (115,686) NR (3,071,255a) Overall Eye and ear 3.47 (1.27–7.56)f
5 (115,686) NR (3,071,255a) Overall Anophthalmia/
microphthalmia
6.91 (2.24–16.14)f
91 (115,686) NR (3,071,255a) Overall Cardiac and circulatory 3.50 (2.81–4.31)f
7 (115,686) NR (3,071,255a) Overall Conotruncal 3.14 (1.26–6.47)f
60 (115,686) NR (3,071,255a) Overall Septal 3.05 (2.32–3.94)f
54 (115,686) NR (3,071,255a) Overall Left ventricular outflow
tract
4.22 (3.16–5.53)f
5 (115,686) NR (3,071,255a) Overall Respiratory 3.58 (1.16–8.36)f
11 (115,686) NR (3,071,255a) Overall Oral clefts 2.69 (1.34–4.82)f
13 (115,686) NR (3,071,255a) Overall Gastrointestinal 1.69 (0.90–2.89)f
5 (115,686) NR (3,071,255a) Overall Gastrointestinal atresia/
stenosis
2.56 (0.83–5.97)f
34 (115,686) NR (3,071,255a) Overall Genitourinary 2.37 (1.64–3.32)f
5 (115,686) NR (3,071,255a) Overall Musculoskeletal 0.88 (0.29–2.06)f
1 (115,686) NR (3,071,255a) Overall Limb reduction 0.80 (0.02–4.49)f
3 (115,686) NR (3,071,255a) Overall Abdominal wall 2.26 (0.47–6.62)f
55 (115,686) NR (3,071,255a) Overall Chromosomal (includes




132 (59,258) NR (NR) Overall Non-chromosomal 1.58 (1.33–1.87)e Children with leukemia were excluded
from the non-chromosomal analysis.
Results for specific BDs exclude
children with chromosomal anomalies.
90 (6,327) NR (NR) Overall Chromosomal 12.44 (10.10–15.32)e
0 (488) NR (NR) Overall Amniotic bands (658) -
0 (423) NR (NR) Overall Anencephalus (740) -
3 (1,124) NR (NR) Overall Spina bifida (741) 3.19 (1.03–9.89)e
35 (7,678) NR (NR) Overall Other BD of nervous
system (742)
5.83 (4.18–8.14)e
24 (6,392) NR (NR) Overall BD of eye (743) 4.90 (3.28–7.32)e
26 (11, 025) NR (NR) Overall BD of ear, face, neck
(744)
2.94 (2.00–4.33)e




23 (7,990) NR (NR) Overall Other BD of heart (746) 3.99 (2.65–6.01)e
21 (6,840) NR (NR) Overall Other BD of circulatory
system (747)
4.28 (2.79–6.57)e
24 (7,958) NR (NR) Overall BD of respiratory system
(748)
4.25 (2.85–6.35)e
5 (4,662) NR (NR) Overall Cleft lip and palate (749) 1.25 (0.52–3.02)e
23 (10,608) NR (NR) Overall Other BD of upper
alimentary (750)
2.45 (1.62–3.69)e
11 (5,419) NR (NR) Overall Other BD of digestive
system (751)
2.44 (1.35–4.40)e
22 (9,522) NR (NR) Overall BD of genital organs (752) 2.62 (1.72–3.98)e
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23 (11,329) NR (NR) Overall Other BD of limbs (755) 2.37 (1.57–3.57)e




31 (11,444) NR (NR) Overall BD of integument (757) 3.09 (2.17–4.40)e





123 (44,151) 161 (147,940) Overall Any BD 2.9 (2.3–3.7)f Children with chromosomal anomalies
were excluded. The relative hazard of
cancer for children with non-
chromosomal anomalies was highest in
the first 3 years of life (figure 3).
77 (39,726) 161 (147,940) Overall Non-chromosomal 2.0 (1.5–2.6)f
9 (4,311) 161 (147,940) Overall Brain 2.2 (1.1–4.3)f
<5 (1,334) 161 (147,940) Overall Neural tube defects, all 2.3 (0.7–7.3)f
<5 (1,108) 161 (147,940) Overall Spina bifida w/out
anencephalus
2.7 (0.9–8.4)f
0 (226) 161 (147,940) Overall Encepahalocele 0.0f
5 (1,801) 161 (147,940) Overall Microcephaly 2.9 (1.2–7.1)f
<5 (63) 161 (147,940) Overall Holoprosencephaly 24.5 (3.4–175.3)f
<5 (1,271) 161 (147,940) Overall Hydrocephalus (no spina
bifida)
0.9 (0.1–6.3)f
8 (928) 161 (147,940) Overall Eye 9.4 (4.6–19.1)f
<5 (432) 161 (147,940) Overall Anophtalmia/
microphthalmia
8.4 (2.7–26.3)f
6 (530) 161 (147,940) Overall Congenital cataract 11.6 (5.1–26.1)f
<5 (31) 161 (147,940) Overall Aniridia 30.8 (4.3–219.9)f
<5 (626) 161 (147,940) Overall Ear (anotia/microtia) 1.7 (0.2–11.9)f
<5 (422) 161 (147,940) Overall Craniosynotosis 3.4 (0.5–24.4)f
28 (11,211) 161 (147,940) Overall Heart 2.9 (1.9–4.3)f
<5 (465) 161 (147,940) Overall Complex heart defects 3.6 (0.5–25.6)f
<5 (172) 161 (147,940) Overall Common truncus 13.1 (1.8–93.3)f
<5 (687) 161 (147,940) Overall Transposition of great
arteries
3.7 (0.9–14.9)f
<5 (759) 161 (147,940) Overall Tetralogy of Fallot 1.6 (0.2–11.4)f
<5 (350) 161 (147,940) Overall Atrioventricular septal
defect (AV canal)
9.1 (2.2–36.6)f
<5 (64) 161 (147,940) Overall Total anomalous
pulmonary venous return
20.5 (2.9–146.4)f
0 (182) 161 (147,940) Overall Pulmonary valve atresia 0.0f
0 (153) 161 (147,940) Overall Tricuspid valve atresia
and stenosis
0.0f
0 (141) 161 (147,940) Overall Ebstein anomaly 0.0f
0 (509) 161 (147,940) Overall Hypoplastic left heart
syndrome
0.0f
<5 (1,024) 161 (147,940) Overall Coarctation of the aorta 1.1 (0.1–7.6)f
<5 (540) 161 (147,940) Overall Aortic valve stenosis 4.5 (1.1–18.1)f
0 (203) 161 (147,940) Overall Other major congenital
heart defects
0.0f
<5 (1,037) 161 (147,940) Overall Pulmonary valve stenosis 2.2 (0.5–8.9)f
5 (2,330) 161 (147,940) Overall Ventricular septal defect,
membranous
2.5 (1.0–6.0)f
<5 (1,276) 161 (147,940) Overall Ventricular septal defect,
NOS
2.2 (0.8–6.1)f
6 (1,404) 161 (147,940) Overall Atrial septal defect 5.1 (2.2–11.4)f
(Continued)
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6 (4,756) 161 (147,940) Overall Orofacial 1.3 (0.6–2.8)f
5 (1,656) 161 (147,940) Overall Cleft palate/without cleft
lip
3.2 (1.3–7.9)f
<5 (3,100) 161 (147,940) Overall Cleft lip with or without
cleft palate
0.3 (0–2.2)f
0 (387) 161 (147,940) Overall Choanal atresia 0.0f
13 (7,207) 161 (147,940) Overall Gastrointestinal (GI) 1.7 (1.0–3.0)f
<5 (1,367) 161 (147,940) Overall GI atresias, all 2.4 (0.8–7.6)f
<5 (562) 161 (147,940) Overall Esophageal atresia/TE
Fistula
2.0 (0.3–14)f
0 (67) 161 (147,940) Overall Duodenal atresia 0.0f
0 (79) 161 (147,940) Overall Jejunal/Ileal atresia 0.0f
0 (9) 161 (147,940) Overall Small intestinal atresia 0.0f
<5 (1,025) 161 (147,940) Overall Rectal/intestinal atresia/
stenosis
3.2 (1.0–10)f
6 (5,071) 161 (147,940) Overall Pyloric stenosis 1.1 (0.5–2.4)f
<5 (377) 161 (147,940) Overall Hirschsprung disease 5.2 (1.3–20.8)f
<5 (163) 161 (147,940) Overall Bilary atresia 15.2 (3.8–61.3)f
<5 (1,479) 161 (147,940) Overall Abdominal wall defects
and variants
2.3 (0.7–7.2)f
<5 (368) 161 (147,940) Overall Omphalocele 3.2 (0.4–22.8)f
<5 (972) 161 (147,940) Overall Gastroschisis 2.3 (0.6–9.3)f
0 (17) 161 (147,940) Overall Cloacal exstrophy 0.0f
0 (66) 161 (147,940) Overall Bladder exstrophy 0.0f
0 (131) 161 (147,940) Overall Epispadias 0.0f
<5 (605) 161 (147,940) Overall Diaphragmatic hernia 5.3 (1.3–21.5)f
20 (10,877) 161 (147,940) Overall Genitourinary (GU) 1.8 (1.2–2.9)f
12 (4,349) 161 (147,940) Overall Renal, all 3.3 (1.8–5.9)f
5 (977) 161 (147,940) Overall Renal agenesis/
hypoplasia
8.3 (3.4–20.2)f
8 (3,561) 161 (147,940) Overall Obstructive GU defect 2.5 (1.2–5.1)f
8 (6,691) 161 (147,940) Overall Hypospadias (includes 1st
degree)
1.1 (0.5–2.2)f
<5 (1,019) 161 (147,940) Overall Limb deficiencies 1.9 (0.5–7.7)f
<5 (663) 161 (147,940) Overall Transverse 3.0 (0.7–12.2)f
<5 (299) 161 (147,940) Overall Preaxial 4.0 (0.6–28.2)f
0 (332) 161 (147,940) Overall Postaxial 0.0f




218 (0) 161 (147,940) Overall Amniotic bands 0.0f
46 (4,425) 161 (147,940) Overall Chromosomal 13.2 (9.5–18.3)f
Sun et al., 2014
[38]
14 (4,484) 207 (1,547,126) Overall (<1 year) Nervous system (cohort
entry on day of birth)
23.41 (13.62–40.22)e Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.NR (NR) NR (NR) Overall (<1 year) Nervous system (cohort
entry at BD diagnosis)
23.86 (11.23–50.70)e
36 (4,484) 1,824 (1,547,126) Overall (1–15 years) Nervous system (cohort
entry on day of birth)
6.58 (4.73–9.16)e
NR (NR) NR (NR) Overall (1–15 years) Nervous system (cohort
entry at BD diagnosis)
5.55 (3.7–8.23)e
12 (24,643) <207 (1,547,126) Overall (<1 year) Circulatory system
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Comments
NR (NR) NR (NR) Overall (<1 year) Circulatory system
(cohort entry at BD
diagnosis)
1.12 (0.28–4.51)e
93 (4,484) 1,824 (1,547,126) Overall (1–15 years) Circulatory system
(cohort entry on day of
birth)
3.31 (2.68–4.07)e
NR (NR) NR (NR) Overall (1–15 years) Circulatory system





94 (32,310) 894a (608,726a) Overall Any BD 1.96 (1.57–2.43)e Any BD included all BDs. Other risk
estimates excluded syndromes known
to be associated with cancer (e.g. DS)
(N category).
3 (1,062) 894a (608,726a) Overall Chromosomal 2.03 (0.66–6.31)e
54 (31,211) 894a (608,726a) Overall Non-chromosomal 1.16 (0.88–1.53)e
0 (1,409) 894a (608,726a) Overall Nervous 0, -e
0 (645) 894a (608,726a) Overall Eye 0, -e
3 (1,479) 894a (608,726a) Overall Ear, face, neck 1.41 (0.46–4.38)e
14 (5,617) 894a (608,726a) Overall Cardiovascular 1.76 (1.04–2.99)e
1 (228) 894a (608,726a) Overall Respiratory 3.64 (0.52–25.63)e
3 (3,318) 894a (608,726a) Overall Gastrointestinal 0.61 (0.20–1.88)e
14 (9,577) 894a (608,726a) Overall Urogenital 0.97 (0.57–1.65)e
14 (8,222) 894a (608,726a) Overall Musculoskeletal 1.14 (0.67–1.93)e
7 (2,348) 894a (608,726a) Overall Skin 1.98 (0.94–4.17)e
5 (3,307) 894a (608,726a) Overall Other 1.04 (0.43–2.51)e
57 (32,273) 894a (608,726a) Overall (all ages > 90
days of follow-up)
N BDs 1.19 (0.91–1.56)e
44 (32,273) 468a (608,726a) Overall (3 months– 4
years)
N BDs 1.74 (1.28–2.37)e
7 (32,273) 83a (608,726 a) Overall (3–12 months) N BDs 1.59 (0.73–3.43)e
37 (31,368) 385a (586,277a) Overall (1–4 years) N BDs 1.77 (1.26–2.48)e
12 (26,598) 232a (485,396a) Overall (5–9 years) N BDs 0.95 (0.53–1.70)e
1 (19,590) 194a (367,319a) Overall (10–14 years) N BDs 0.10 (0.01–0.72)e
Janitz et al.,
2016 [35]
56 (23,368) 475 (567,867) Overall Any BD (w/chromosomal) 3.0 (2.2–3.9)e† HRs were estimated at each age.
Specific type BD analyses exclude
children with chromosomal anomalies
unless specifically noted that they are
included (w/chromosomal). The authors
note that the proportional hazards
assumption was not met for the overall
association and that a continuous time
interaction model was used for those
noted with an ‘†’. The HRs for
genitourinary and musculoskeletal(non-
chromosomal) were adjusted for
maternal education and prenatal care,
respectively.
NA NA Overall (<1 year) Any BD (w/chromosomal) 14.1 (8.3–23.7)e
NA NA Overall (3 years) Any BD (w/chromosomal) 2.3 (1.6–3.2)e
NA NA Overall (6 years) Any BD (w/chromosomal) 1.1 (0.7–1.9)e
NA NA Overall (9 years) Any BD (w/chromosomal) 0.8 (0.4–1.4)e
NA NA Overall (12 years) Any BD (w/chromosomal) 0.6 (0.3–1.1)e
12a (1,259) NR (NR) Overall Chromosomal 11.9 (6.7–12.2)e†
NA NA Overall (<1 year) Chromosomal 84.7 (33.8–211.9)e
NA NA Overall (3 years) Chromosomal 7.3 (3.2–16.6)e
NA NA Overall (6 years) Chromosomal 2.9 (0.8–9.6)e
NA NA Overall (9 years) Chromosomal 1.6 (0.4–7.1)e
NA NA Overall (12 years) Chromosomal 1.1 (0.2–5.9)e
NR (2,143) NR (NR) Overall CNS (w/chromosomal) 3.0 (1.2–7.2)e†
NA NA Overall (<1 year) CNS (w/chromosomal) 18.8 (4.6–77.8)e
NA NA Overall (3 years) CNS (w/chromosomal) 2.0 (0.6–6.5)e
NA NA Overall (6 years) CNS (w/chromosomal) 0.8 (0.1–4.9)e
NA NA Overall (9 years) CNS (w/chromosomal) 0.5 (0.1–4.3)e
NA NA Overall (12 years) CNS (w/chromosomal) 0.3 (0.0–4.0)e
NR (1,179) NR (NR) Overall Eye/Ear (w/chromosomal) 3.6 (1.4–9.7)e†
NA NA Overall (<1 year) Eye/Ear (w/chromosomal) 27.9 (6.1–127.0)e
NA NA Overall (3 years) Eye/Ear (w/chromosomal) 2.2 (0.5–9.1)e
NA NA Overall (6 years) Eye/Ear (w/chromosomal) 0.8 (0.1–6.8)e
(Continued)
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NA NA Overall (9 years) Eye/Ear (w/chromosomal) 0.4 (0.0–5.9)e
NA NA Overall (12 years) Eye/Ear (w/chromosomal) 0.3 (0.0–5.4)e
NR (7,059) NR (NR) Overall Cardiovascular (w/
chromosomal)
4.4 (2.9–6.6)e†
NA NA Overall (<1 year) Cardiovascular (w/
chromosomal)
22.5 (11.0–46.1)e
NA NA Overall (3 years) Cardiovascular (w/
chromosomal)
3.2 (1.9–5.4)e
NA NA Overall (6 years) Cardiovascular (w/
chromosomal)
1.5 (0.7–3.2)e
NA NA Overall (9 years) Cardiovascular (w/
chromosomal)
0.9 (0.4–2.5)e
NA NA Overall (12 years) Cardiovascular (w/
chromosomal)
0.7 (0.2–2.1)e
NR (1997) NR (NR) Overall Orofacial (w/
chromosomal)
2.5 (0.9–6.6)e
NR (3,736) NR (NR) Overall Gastrointestinal (w/
chromosomal)
2.4 (1.4–5.1)e†
NA NA Overall (<1 year) Gastrointestinal (w/
chromosomal)
21.1 (7.0–63.2)e
NA NA Overall (3 years) Gastrointestinal (w/
chromosomal)
1.1 (0.3–3.8)e
NA NA Overall (6 years) Gastrointestinal (w/
chromosomal)
0.3 (0.1–2.2)e
NA NA Overall (9 years) Gastrointestinal (w/
chromosomal)
0.2 (0.0–1.6)e
NA NA Overall (12 years) Gastrointestinal (w/
chromosomal)
0.1 (0.0–1.3)e
NR (4,124) NR (NR) Overall Genitourinary (w/
chromosomal)
2.5 (1.3–5.1)e†
NA NA Overall (<1 year) Genitourinary (w/
chromosomal)
15.6 (5.0–48.6)e
NA NA Overall (3 years) Genitourinary (w/
chromosomal)
1.6 (0.6–4.3)e
NA NA Overall (6 years) Genitourinary (w/
chromosomal)
0.7 (0.2–2.9)e
NA NA Overall (9 years) Genitourinary (w/
chromosomal)
0.4 (0.1–2.4)e
NA NA Overall (12 years) Genitourinary (w/
chromosomal)
0.3 (0.0–2.1)e
NR (6,825) NR (NR) Overall Musculoskeletal (w/
chromosomal)
1.2 (0.6–2.6)e†
NA NA Overall (<1 year) Musculoskeletal (w/
chromosomal)
5.3 (1.4–20.5)e
NA NA Overall (3 years) Musculoskeletal (w/
chromosomal)
1.0 (0.4–2.5)e
NA NA Overall (6 years) Musculoskeletal (w/
chromosomal)
0.6 (0.2–2.0)e
NA NA Overall (9 years) Musculoskeletal (w/
chromosomal)
0.4 (0.1–1.9)e
NA NA Overall (12 years) Musculoskeletal (w/
chromosomal)
0.3 (0.0–1.8)e
44 (22,109a) 475 (567,867) Overall Non-chromosomal 2.5 (1.8–3.3)e†
NA NA Overall (<1 year) Non-chromosomal 10.7 (6.0–19.1)e
NA NA Overall (3 years) Non-chromosomal 2.0 (1.4–2.9)e
NA NA Overall (6 years) Non-chromosomal 1.0 (0.6–1.8)e
NA NA Overall (9 years) Non-chromosomal 0.7 (0.4–1.4)e
NA NA Overall (12 years) Non-chromosomal 0.5 (0.3–1.2)e
(Continued)
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NR (1,998) NR (NR) Overall CNS 1.9 (0.6–5.9)e†
NR (1,179) NR (NR) Overall Eye/Ear 2.0 (0.5–8.1)e
NR (3,369) NR (NR) Overall Cardiovascular 2.8 (1.7–4.8)e†
NA NA Overall (<1 year) Cardiovascular 11.1 (4.2–29.4)e
NA NA Overall (3 years) Cardiovascular 2.4 (1.3–4.4)e
NA NA Overall (6 years) Cardiovascular 1.3 (0.5–3.2)e
NA NA Overall (9 years) Cardiovascular 0.9 (0.3–2.8)e
NA NA Overall (12 years) Cardiovascular 0.7 (0.2–2.6)e
NR (1,887) NR (NR) Overall Orofacial 2.6 (1.0–6.9)e
NR (3,552) NR (NR) Overall Gastrointestinal 2.2 (1.0–4.9)e†
NA NA Overall (<1 year) Gastrointestinal 18.5 (5.7–60.2)e
NA NA Overall (3 years) Gastrointestinal 1.0 (0.3–3.8)e
NA NA Overall (6 years) Gastrointestinal 0.3 (0.0–2.4)e
NA NA Overall (9 years) Gastrointestinal 0.2 (0.0–1.8)e
NA NA Overall (12 years) Gastrointestinal 0.1 (0.0–1.5)e
NR (3,932) NR (NR) Overall Genitourinary 1.7 (0.7–4.0)e†
NA NA Overall (<1 year) Genitourinary 3.6 (0.5–26.4)e
NA NA Overall (3 years) Genitourinary 1.2 (0.4–3.6)e
NA NA Overall (6 years) Genitourinary 0.8 (0.2–3.8)e
NA NA Overall (9 years) Genitourinary 0.7 (0.1–4.5)e
NA NA Overall (12 years) Genitourinary 0.6 (0.1–5.1)e
NR (6,575) NR (NR) Overall Musculoskeletal 1.3 (0.6–2.8)e
Leukemias, myeloproliferative diseases, myelodysplastic diseases, and lymphoma case-control studies
Ager et al., 1965
[39]
112 (5) Siblings: 105 (3);
Neighborhood:
112 (1)




DS cases were excluded.
Me´hes et al.,
1985 [19]
49 (37) 37 (25) sibling,
49 (19) controls




Major anomalies were also reported;
however there was insufficient detail to
evaluate associations. The authors note
two ALL cases with DS and fetal
hydantoin syndrome were excluded.
Shu et al., 1988
[48]
309 (0) 618 (0) Leukemia Any BD ND The only BD noted was one DS case.
Magnani et al.,
1990 [47]
142 (4) 307 (6) ALL Any BD 1.45 (0.40–5.24)a,b DS cases were excluded.
22 (0) 307 (6) AML Any BD -
19 (0) 307 (6) NHL Any BD -
Zack et al., 1991
[40]
411 (31) 2,055 (99) All leukemias Any BD 1.6 (1.1–2.4)b The authors note that only children with
DS or cleft lip or palate had an
increased risk of leukemia.
411 (3) 2,055 (3) All leukemias Cleft lip or cleft palate 5.0 (1.0–24.8)b
411 (19) 2,055 (80) Lymphatic leukemias Any BD 1.2 (0.7–2.0)b
411 (3) 2,055 (3) Lymphatic leukemias Cleft lip or cleft palate 5.0 (1.0–24.8)b
411 (10) 2,055 (11) Myeloid leukemias Any BD 5.2 (2.1–12.9)b
411 (0) 2,055 (0) Myeloid leukemias Cleft lip or cleft palate ND
411 (2) 2,055 (8) Other or unspecified
leukemias
Any BD 1.3 (0.3–6.5)b
411 (0) 2,055 (8) Cleft lip or cleft palate ND
Schumacher et
al., 1992 [23]
227 (61a) 200 (11) ALL Rib 6.31 (3.21–12.40)a,b
63 (7a) 200 (11) NHL Rib 2.15 (0.80–5.80)a,b
54 (4a) 200 (11) HD Rib 1.37 (0.42–4.50)a,b
Mann et al.,
1993 [16]
148 (11) 148 (8) ALL Any BD 1.41 (0.55–3.60)a,b DS occurred in three leukemia cases. A
variety of BDs were reported in single
cases and controls but no formal
analysis was done. Estimates adjusted
for diagnosis age, sex, and diagnosis
year. Pedigree was shown for one case
with a ALL.
23 (3) 23 (0) Other leukemias Any BD ND
32 (4) 32 (1) HL Any BD 4.43 (0.47–42.02)a,b
31 (3) 31 (4) Other lymphomas Any BD 0.72 (0.15–3.54)a,b
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71 (6) 212 (11) ALL Major 2.1 (0.8–7.8)b DS exclusion not noted. Estimates
adjusted for diagnosis age, sex, and
diagnosis year.
26 (2) 212 (11) Lymphoma Major 1.6 (0.3–7.5)b
Cnattingius et
al., 1995 [49]
613 (NR) 3,065 (NR) Lymphatic leukemia Cleft lip or palate (ICD-8
code 749)
2.0 (0.4–10.3)b Authors’ note: "Among infants with
congenital malformations, only those
with Down’s syndrome . . . had an
increased risk of lymphatic leukemia."
The authors did not report risk
estimates for BDs overall.
Cnattingius et
al., 1995 [41]
84 (5) 490 (18) Myeloid leukemia Any BD 1.4 (0.5–3.8)b DS cases were excluded.
84 (3) 490 (3) Myeloid leukemia Heart 5.0 (1.01–24.8)b
Adami et al.,
1996 [54]
168 (5) 840 (37) NHL Any BD (ICD-9 codes
740–759)
0.7 (0.3–1.7)b DS exclusion not noted.
Altmann et al.,
1998 [17]
224 (19) NR (NR) Leukemia Any BD 3.7 (2.2–6.5)b DS cases were not excluded except
where noted. Any BD estimates
adjusted for 6-month calendar period,
gender, birth weight, gestational age,
and maternal age.
185 (9) NR (NR) ALL Any BD 2.0 (0.96–4.1)b
32 (7) NR (NR) AML Any BD 11.6 (4.6–29.4)b
32 (1) NR (3) AML Non-DS chromosomal 20.3 (1.8–224)b
45 (2) NR (NR) Lymphoma Any BD 2.1 (0.5–9.2)b
Me´hes et al.,
1998 [52]
100 (82a) Controls: 200
(83a); Siblings: 80
(69a)
Leukemia Mild errors of
morphogenesis (55
MEMs based on Pinsky et
al.[111])
NR DS exclusion not noted. Case and
control mean MEM numbers were 1.59
and 0.69 (p<0.01); Cases and sibling




2,117 (526) 2,368 (443) ALL Overall (at least 1 BD) 1.43 (1.25–1.66)a,b Estimates adjusted for maternal race,
maternal education, and family income.
After exclusion of DS cases, the
significant associations between
pancreatic or digestive tract
abnormalities and ALL and between
multiple birthmarks and both ALL and
AML remained.
2,117 (664) 2,368 (552) ALL Total no. of abnormalities 1.50 (1.32–1.72)b
2,117 (4) 2,368 (10) ALL Cleft lip or palate 0.45 (0.14–1.38)b
2,117 (5) 2,368 (7) ALL Club foot 0.80 (0.25–2.51)b
2,117 (161) 2,368 (136) ALL Large or multiple
birthmarks
1.35 (1.07–1.71)b
2,117 (8) 2,368 (8) ALL Deafness or impaired
hearing
1.12 (0.42–2.99)b
2,117 (20) 2,368 (18) ALL Blindness or difficulty
seeing
1.25 (0.66–2.36)b
2,117 (10) 2,368 (4) ALL Eyes different colors or
missing iris
2.81 (0.92–8.53)b
2,117 (5) 2,368 (3) ALL Water on the brain or
hydrocephalus
1.87 (0.46–7.64)b
2,117 (4) 2,368 (3) ALL Spina bifida or other
spinal
1.49 (0.34–6.61)b
2,117 (2) 2,368 (7) ALL Cerebral palsy 0.32 (0.07–1.42)b
2,117 (3) 2,368 (2) ALL Unusually small head or
microcephaly
1.68 (0.29–9.86)b
2,117 (3) 2,368 (2) ALL Unequal sized limbs or
hemihypertrophy
1.68 (0.29–9.86)b
2,117 (73) 2,368 (72) ALL Any skeletal deformity 1.14 (0.82–1.59)b
2,117 (98) 2,368 (75) ALL Hole in heart or other
heart
1.48 (1.09–2.01)b
2,117 (29) 2,368 (13) ALL Pancreas or digestive
tract
2.52 (1.33–4.75)b
2,117 (47) 2,368 (49) ALL Any other BDs 1.08 (0.72–1.61)
2,117 (39) 2,368 (31) ALL Genitourinary 1.42 (0.88–2.27)b
605 (149) 769 (115) AML Overall (at least 1 BD) 1.86 (1.42–2.44)a,b
605 (231) 769 (135) AML Total no. of abnormalities 2.90 (2.27–3.70)b
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605 (5) 769 (1) AML Cleft lip or palate 6.40 (0.98–41.64)b
605 (1) 769 (2) AML Club foot 0.64 (0.06–6.88)b
605 (39) 769 (27) AML Large or multiple
birthmarks
1.89 (1.15–3.11)b
605 (5) 769 (1) AML Deafness or impaired
hearing
6.40 (0.98–41.64)b
605 (3) 769 (7) AML Blindness or difficulty
seeing
0.54 (0.14–2.07)b
605 (0) 769 (0) AML Eyes different colors or
missing iris
-
605 (3) 769 (2) AML Water on the brain or
hydrocephalus
1.91 (0.33–11.14)b
605 (3) 769 (1) AML Spina bifida or other
spinal defect
3.83 (0.47–31.45)b
605 (3) 769 (0) AML Unusually small head or
microcephaly
ND
605 (2) 769 (0) AML Unequal sized limbs or
hemihypertrophy
ND
605 (16) 769 (12) AML Any skeletal deformity 1.71 (0.81–3.62)b
605 (27) 769 (17) AML Hole in heart or other
heart
2.07 (1.13–3.78)b
605 (6) 769 (4) AML Pancreas or digestive
tract
1.92 (0.55–6.68)b
605 (7) 769 (11) AML Genitourinary 0.81 (0.31–2.09)b
605 (10) 769 (17) AML Other BDs 0.74 (0.34–1.63)b
Infante-Rivard et
al., 2001 [42]
491 (49) 491 (46) ALL Any BD 1.07 (0.70–1.65)b DS exclusion not noted. Estimates
adjusted for maternal education,
paternal and maternal age.
Roganovic et al.,
2002 [50]
64 (55) 64 (43) Hematologic
malignancies (HM)
Any minor 2.98 (1.24–7.17)a,b DS exclusion not noted. The authors
also reported data for ALL, AML, NHL
and HD but did not report the overall
number of cases who had at least one
minor anomaly for each of these
subtypes. The authors also noted “a




26 (0) 881 (54) AML Cervical rib -
132 (16) 881 (54) ALL Cervical rib 2.11 (1.17–3.81)a,b
92 (5) 881 (54) HD Cervical rib 0.88 (0.34–2.26)a,b
106 (8) 881 (54) NHL Cervical rib 1.25 (0.58–2.70)a,b
Podvin et al.,
2006 [44]
595 (11) 5,950 (93) Leukemia Other malformations (not
DS)
1.2 (0.6–2.2)b Estimates adjusted for maternal age.
Loder et al.,
2007 [25]
109a (16) 200 (16) ALL, AML, lymphoma Abnormal rib number
(normal = 24 ribs)




443 (77) 324 (40) All infant leukemia Any BD 1.2 (0.8–1.9)b DS cases excluded. Estimates adjusted
for birth year and follow-up time.443 (41) 324 (18) All infant leukemia Large or multiple
birthmarks
1.3 (0.7–2.4)b
443 (9) 324 (9) All infant leukemia Urogenital system 0.7 (0.2–2.0)b
443 (29) 324 (15) All infant leukemia Other 1.4 (0.7–2.8)b
264 (47) 324 (40) Infant ALL Any BD 1.4 (0.8–2.3)b
264 (26) 324 (18) Infant ALL Large or multiple
birthmarks
1.5 (0.8–3.0)b
264 (5) 324 (9) Infant ALL Urogenital system 0.8 (0.2–2.6)b
264 (17) 324 (15) Infant ALL Other 1.5 (0.7–3.3)b
172 (30) 324 (40) Infant AML Any BD 1.4 (0.8–2.4)b
172 (15) 324 (18) Infant AML Large or multiple
birthmarks
1.4 (0.6–2.9)b
172 (4) 324 (9) Infant AML Urogenital system 0.7 (0.2–3.2)b
172 (12) 324 (15) Infant AML Other 1.6 (0.7–3.8)b
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Citak et al., 2011
[51]
109 (70) 109 (29) HM Minor 4.95 (2.78–8.82)a,b Cases with major malformations and
syndromes were excluded. Among
minor anomalies, pigmented nevi and
cafe´-au-lait spots were significantly
more frequent in the cases.
Durmaz et al.,
2011 [20]
112 (109a) 200 (70a) HM Any minor 67.48 (20.7–220.3)a,b Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported (not
shown).
112 (22) 200 (13) HM Hand 3.5 (1.69–7.29)b
112 (34) 200 (7) HM Feet 12.02 (5.11–28.25)b
112 (53) 200 (37) HM Eye 3.9 (2.36–6.62)b
112 (9) 200 (7) HM Nose 2.4 (0.87–6.65)b
112 (64) 200 (27) HM Mouth 8.5 (4.92–14.83)b
112 (49) 200 (8) HM Ear 18.7 (8.4–41.53)b
Zierhut et al.,
2011 [24]
221 (15) 1,133 (51) Leukemias, MPD, MDS Abnormal ribs (normal =
24 ribs)
1.55 (0.84–2.88)b Estimates adjusted for sex and age.
105 (6) 1,133 (51) Lymphoid leukemias Abnormal ribs 1.27 (0.51–3.11)b
78 (8) 1,133 (51) AML Abnormal ribs 2.29 (1.02–5.13)b




18 (1) 1,133 (51) Other specified or
unspecified leukemias
Abnormal ribs 1.16 (0.15–8.98)b
50 (1) 1,133 (51) Lymphomas and
reticuloendothelial
neoplasms
Abnormal ribs 0.37 (0.05–2.89)b
29 (0) 1,133 (51) HL Abnormal ribs -
12 (1) 1,133 (51) NHL (except Burkitt’s
lymphoma)
Abnormal ribs 1.67 (0.21–13.41)b





764 (35) 1,681 (51) Acute leukemia Any BD 1.5 (1.0–2.4)b DS cases excluded. Estimates adjusted
for age x gender, maternal age at child’s
birth, parental professional category. P-
values were calculated by Fisher’s
exact test.
764 (26) 1,681 (32) Acute leukemia Minor 1.8 (1.0–3.1)b
764 (9) 1,681 (19) Acute leukemia Major 1.1 (0.5–2.4)b
764 (3) 1,681 (6) Acute leukemia Face/tongue/mouth 0.9 (0.2–3.7)b
764 (3) 1,681 (9) Acute leukemia Heart 0.7 (0.2–2.8)b
764 (4) 1,681 (1) Acute leukemia Digestive tract 0.01<p<0.05
764 (7) 1,681 (10) Acute leukemia Urinary system 1.7 (0.6–4.7)b
764 (3) 1,681 (6) Acute leukemia Genital organs 1.0 (0.2–4.2)b
764 (9) 1,681 (23) Acute leukemia Skeleton 0.8 (0.4–1.9)b
764 (5) 1,681 (0) Acute leukemia Skin 0.001<p<0.01
764 (2) 1,681 (0) Acute leukemia Nervous System NR
648 (28) 1,681 (51) ALL Any BD 1.4 (0.9–2.2)b
648 (20) 1,681 (32) ALL Minor 1.6 (0.9–2.8)b
648 (8) 1,681 (19) ALL Major 1.1 (0.5–2.5)b
648 (2) 1,681 (6) ALL Face/tongue/mouth 0.7 (0.1–3.5)b
648 (2) 1,681 (9) ALL Heart 0.5 (0.1–2.6)b
648 (4) 1,681 (1) ALL Digestive tract 0.01< p<0.05
648 (6) 1,681 (10) ALL Urinary system 1.6 (0.6–4.9)b
648 (2) 1,681 (6) ALL Genital organs 0.8 (0.1–3.9)b
648 (8) 1,681 (23) ALL Skeleton 0.9 (0.4–2.0)b
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648 (5) 1,681 (0) ALL Skin NR
648 (0) 1,681 (0) ALL Nervous System NR
101 (6) 1,681 (51) AML Any BD 2.3 (1.0–5.7)b
101 (5) 1,681 (32) AML Minor 3.0 (1.1–8.2)b
101 (1) 1,681 (19) AML Major NR
18 (0) NR (NR) Pro-B Any BD -
508a (22) NR (NR) Pre-B/Common B Any BD 1.3 (0.8–2.2)b
32 (0) NR (NR) B mature Any BD -
67 (5) NR (NR) T-cell Any BD 2.4 (0.9–6.3)
Leukemias, myeloproliferative diseases, myelodysplastic diseases, and lymphoma cohort studies
Windham et al.,
1985 [27]
20 (22,856) NR (NR) Leukemia Any BD 2.4 (1.6–3.7)c The authors note that most of the
excess was due to DS cases.
Estimates are age standardized.
NR (NR) NR (NR) Leukemia Any BD (Male) 2.6c*
NR (NR) NR (NR) Leukemia Any BD (Female) 2.2c*
NR (NR) NR (NR) Leukemia (0–4 years) Any BD (Male) 2.4c*
NR (NR) NR (NR) Leukemia (0–4 years) Any BD (Female) 2.4c*
NR (NR) NR (NR) Leukemia (5–9 years) Any BD (Male) 3.9c*
NR (NR) NR (NR) Leukemia (5–9 years) Any BD (Female) 1.7c*
Mili et al., 1993
[28]
8 (19,373) 116 (544,304) Leukemia Any BD 2.0 (0.8–3.9)d; 1.2
(0.40–2.9)d DS
excluded
Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.
Mili et al., 1993
[29]
3 (10,891) 102 (241,473) Leukemia Any BD 1.1 (0.2–3.2)d; 0.36
(0.009–2.0)d DS
excluded
Leukemia was only associated with DS.
Estimates adjusted for age and sex.
Agha et al.,
2005 [33]
48 (45,200) 19 (45,200) Leukemia Any BD 2.7 (2.1–3.6)c Did not exclude any known genetic
syndromes. O/E ratios are age
standardized.
NA NA Leukemia Chromosomal 8.8 (5.2–14.8)g
8 (45,200) 9 (45,200) Lymphoma Any BD 1.0 (0.6–1.6)c





10 (NR) 218a (NR) ALL Any BD 2.73 (1.49–5.02)f The authors report that the association
between leukemia and BDs was still
present after excluding DS cases.
7 (NR) 19a (NR) AML Any BD 21.97 (12.07–39.96)f
1 (NR) 8a (NR) Other leukemia Any BD 7.45 (1.27–43.60)f
5 (NR) 56a (NR) HL and NHL Any BD 5.32 (2.35–12.04)f
Carozza et al.,
2012 [31]
84 (115,686) 742 (3,071,255a) Leukemia Any BD 1.39 (1.09–1.75)f Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
8 (115,686) 137 (3,071,255a) Lymphoma Any BD 1.80 (0.76–3.64)f
Fisher et al.,
2012 [36]
29 (59,258) NR Leukemia Non-chromosomal 0.96 (0.66–1.38)e
77 (6,327) NR Leukemia Chromosomal 28.99 (23.07–36.42)e
33 (6,327) NR ALL Chromosomal 14.95 (10.59–21.11)e
35 (6,327) NR AML Chromosomal 101.22 (70.87–
144.57)e
17 (59,258) NR Lymphoma Non-chromosomal 2.24 (1.38–3.63)e
Botto et al.,
2013 [32]
13 (44,151) 45 (147,940) Leukemia Structural 1.19 (0.6–2.2)f Children with chromosomal anomalies
were excluded.12 (44,151) 36 (147,940) ALL Structural 1.38 (0.7–2.6)f
<5 (44,151) 5 (147,940) AML Structural 0.83 (0.1–7.1)f
0 (44,151) <5 (147,940) Other and unspecified Structural -
<5 (44,151) <5 (147,940) MDS/MPD Structural 12.41 (1.3–119.3)f
<5 (44,151) 10 (147,940) Lymphoma Structural 1.65 (0.5–5.3)f
<5 (44,151) 6 (147,940) NHL Structural 0.69 (0.1–5.7)f
<5 (44,151) <5 (147,940) HL Structural 1.03 (0.1–9.2)f
<5 (44,151) 0 (147,940) Other, unspecified Structural -
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Sun et al., 2014
[38]
1 (4,484) 47 (1,547,126) LHT (<1 year) Nervous system (cohort
entry on day of birth)
7.35 (1.01–53.3)e Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.NR (NR) NR (NR) LHT (<1 year) Nervous system (cohort
entry at BD diagnosis)
-
5 (4,484) 787 (1,547,126) LHT (1–15 years) Nervous system (cohort
entry on day of birth)
2.12 (0.88–5.11)e
NR (NR) NR (NR) LHT (1–15 years) Nervous system (cohort
entry at BD diagnosis)
1.56 (0.50–4.85)e
4 (24,643) 47 (1,547,126) LHT (<1 year) Circulatory system
(cohort entry on day of
birth)
5.34 (1.92–14.83)e
NR (NR) NR (NR) LHT (<1 year) Circulatory system
(cohort entry at BD
diagnosis)
2.36 (0.33–17.08)e
40 (4,484) 787 (1,547,126) LHT (1–15 years) Circulatory system
(cohort entry on day of
birth)
3.27 (2.38–4.49)e
NR (NR) NR (NR) LHT (1–15 years) Circulatory system





13 (32,273) 291a (608,726) Leukemia MPD and
MPS
N BDs 0.83 (0.48–1.44)e Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).9 (32,273) 242a (608,726) ALL N BDs 0.69 (0.36–1.34)e
1 (32,273) 36a (608,726) AML N BDs 0.52 (0.07–3.76)e
7 (32,273) 9a (608,726) Other leukemias N BDs 4.30 (1.23–15.09)e
3 (32,273) 85a (608,726) Lymphoma N BDs 1.63 (0.75–3.53)e
Janitz et al.,
2016 [35]
18 (23,368a) 194a (567,867) Leukemia Any BD (w/chromosomal) 2.3 (1.4–3.8)e For lymphoma, the exact number of
cases was suppressed.10 (22,109a) 194a (567,867) Leukemia Non-chromosomal 1.4 (0.7–2.6)e
5 (22,109a) 39a (567,867) Lymphoma Any BD (w/chromosomal) 2.8 (1.0–7.9)e
5 (22,109a) 39a (567,867) Lymphoma Non-chromosomal 3.0 (1.1–8.4)e
Leukemias, myeloproliferative diseases, myelodysplastic diseases, and lymphoma case series with an external comparison group studies
Narod et al.,
1997 [53]
6,588 (6) NA Leukemia Spina bifida 0.76 (NRCT); 1.8
(BC)
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.
6,588 (8) NA Leukemia Cardiac septal 0.54; 0.28
6,588 (36) NA Leukemia Genitourinary 0.64; 0.56
6,588 (6) NA Leukemia Spine and rib 0.4; 3.1*
2,191 (3) NA Lymphoma Cardiac septal 0.61; 0.31
2,191 (20) NA Lymphoma Genitourinary 1.1; 0.94
2,191 (7) NA Lymphoma Spine and rib 1.3; 10.9**
Central nervous system and miscellaneous intracranial and intraspinal neoplasms case-control studies
Johnson et al.,
1987 [62]
499 (NR) 998 (NR) CNS Any BD NR Genetic syndromes were not noted as
excluded; The authors concluded that
there was no association.
Baptiste et al.,
1989 [55]
338 (14) 676 (28) CNS Any BD 1.00 (0.49–2.00)h Does not include Neurofibromatosis
Type 1 cases.
Birch et al., 1990
[56]
78 (16) 78 (7) CNS Any BD 2.6 (0.9–7.6)h Hospital controls and children with
single small birthmarks were excluded.78 (10) 78 (4) CNS Medically confirmed BDs 2.7 (0.7–10.9)h
Schumacher et
al., 1992 [23]
234 (64a) 200 (11) Brain Rib 6.47 (3.30–12.67)a,b
Mann et al.,
1993 [16]
78 (10) 78 (3) CNS Any BD 3.68 (0.97–13.92)a,b No CNS tumor cases were noted with
genetic syndromes; Four cases were
reported by Birch et al. [56] but one




75 (NR) 113 (NR) Brain BDs (excluding minor) NR The authors note that the percentage of
children reported with BDs (excluding
minor anomalies) was higher among
controls (11%) than cases (7%).
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Gold et al., 1994
[64]
361 (1) 1,086 (6) Brain Ear/Congenital deafness 0.50 (0.06–4.17)a,b
361 (3) 1,086 (3) Brain Vertebral/back/curvature
of the spine
3.03 (0.61–15.06)a,b
361 (3) 1,086 (6) Brain Eye 1.50 (0.38–6.06)a,b
361 (0) 1,086 (1) Brain Cleft lip or palate -
361 (1) 1,086 (0) Brain Hydrocephalus -
361 (0) 1,086 (9) Brain Congenital heart disease -
361 (0) 1,086 (7) Brain Polydactyly/other digit -
361 (4) 1,086 (0) Brain Neurofibromatosis -
361 (0) 1,086 (4) Brain Absent/extra/deformed
kidney
-
361 (0) 1,086 (1) Brain Spina bifida -
361 (5) 1,086 (3) Brain Club foot 5.07 (1.21–21.32)a,b
361 (1) 1,086 (10) Brain Digestive System 0.30 (0.04–2.34)a,b
361 (2) 1,086 (2) Brain Other urogenital system 3.02 (0.42–21.51)a,b
361 (14) 1,086 (27) Brain Other/multiple 1.58 (0.82–3.05)a,b
McCredie et al.,
1994 [65]




47 (3) 212 (11) CNS Major 1.2 (0.3–4.7)b Genetic syndromes were not noted as
excluded. All cases were noted to have
had a CT scan but not controls.
Altmann et al.,
1998 [17]
92 (9) NR (NR) CNS Any BD 4.7 (2.2–10.0)b DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age, and maternal age.
92 (4) NR (3) CNS Nervous system 27.8 (6.1–127)b
92 (2) NR (11) CNS Eye/face/neck 16.8 (2.7–103)b
39 (3) NR (NR) AST Any BD 3.5 (0.98–12.5)b
Merks et al.,
2005 [26]
21 (2) 881 (54) MB Cervical 1.61 (0.37–7.10)a,b
22 (4) 881 (54) AST Cervical 3.40 (1.11–10.41)a,b
Loder et al.,
2007 [25]
37 (13) 200 (16) Neural (CNS) Abnormal rib number
(normal = 24 ribs)
6.23 (2.7–14.5)b Children with a known BD or DS were
excluded.
Mallol-Mesnard
et al., 2008 [58]
209 (8) 1,681 (57) All CNS Any BD 1.1 (0.5–2.3)b Estimates adjusted for age and sex.
209 (6) 1,681 (38) All CNS Major 1.2 (0.5–2.9)b
33 (1) 1,681 (57) EPD Any BD 1.0 (0.1–7.2)b
100 (3) 1,681 (57) Embryonal Any BD 0.8 (0.2–2.6)b
100 (2) 1,681 (38) Embryonal Major 0.8 (0.2–3.5)b
26 (1) 1,681 (57) AST Any BD 1.2 (0.2–9.2)b
26 (1) 1,681 (38) AST Major 1.9 (0.2–14)b
45 (3) 1,681 (57) Other gliomas Any BD 2.0 (0.6–6.6)b
45 (3) 1,681 (38) Other gliomas Major 2.9 (0.9–10)b
Durmaz et al.,
2011 [20]
28 (9) 200 (13) CNS Hand 6.8 (2.57–18.01)b Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported.
28 (9) 200 (7) CNS Feet 13.06 (4.37–39.01)b
28 (16) 200 (37) CNS Eye 5.9 (2.56–13.46)b
28 (4) 200 (7) CNS Nose 4.6 (1.25–16.85)b
28 (24) 200 (27) CNS Mouth 38.4 (12.37–119.43)b
28 (11) 200 (8) CNS Ear 15.5 (5.50–43.80)b
Partap et al.,
2011 [57]
3,733 (45) 14,932 (90) CNS Any BDs 1.82 (1.25–2.65)b Estimates adjusted for birth weight, birth
order, race, Hispanic ethnicity, and
maternal age.
NR (NR) NR (NR) CNS (<2 years) Any BD 1.70 (1.12–2.57)b
NR (NR) NR (NR) CNS (<1 year) Any BD 2.91 (1.68–5.05)b
1,380 (NR) 14,932 (90) LGG Any BDs 0.71 (0.29–1.72)b
757 (NR) 14,932 (90) HGG Any BDs 0.64 (0.19–2.24)b
516 (NR) 14,932 (90) MB Any BDs 3.19 (1.29–7.87)b
402 (NR) 14,932 (90) PNET Any BDs 2.97 (1.21–7.28)b
187 (NR) 14,932 (90) GCT Any BDs 7.20 (2.10–24.63)b
292 (NR) 14,932 (90) EPD Any BDs 1.17 (0.13–10.61)b
(Continued)
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34 (3) 1,133 (51) CNS and miscellaneous
intracranial and
intraspinal neoplasms
Abnormal ribs 2.00 (0.59–6.77)b Estimates adjusted for sex and age.
Greenop et al.,
2014 [60]
282 (14) 898 (38) CBT BD 1.17 (0.63–2.2)a,b
Bailey et al.,
2017 [59]
510 (19a) 3,102 (109a) Any CBT BD 1.0 (0.6–1.6)b Estimates adjusted for sex and age.
64 (3a) 3,102 (109a) EPD BD 1.4 (0.4–4.5)b
120 (5a) 3,102 (109a) AST BD 1.2 (0.5–2.9)b
206 (7a) 3,102 (109a) Embryonal BD 0.9 (0.4–1.9)b
109 (4a) 3,102 (109a) Other gliomas BD 1.0 (0.4–2.8)b
Central nervous system and miscellaneous intracranial and intraspinal neoplasms cohort studies
Windham et al.,
1985 [27]
9 (22,856) NR (NR) Nervous system Any BD 1.7 (0.9–3.2)c Did not exclude any known genetic
syndromes. Estimates are age
standardized. The authors note that the
RR = 34.7 was significant and that risk
was limited to first two years of life.
6 (NR) NR (NR) CNS tumor (malignant
and benign)
CNS defect 34.7c* (NR)
NR (NR) NR (NR) Nervous system Male 2.0c
NR (NR) NR (NR) Nervous system Female 1.3c
NR (NR) NR (NR) Nervous system (0–4
years)
Male 2.6c*
NR (NR) NR (NR) Nervous system (0–4
years)
Female 1.3c
NR (NR) NR (NR) Nervous system (5–9
years)
Male 1.2c
NR (NR) NR (NR) Nervous system (5–9
years)
Female 1.4c
Mili et al., 1993
[28]
10 (19,373) 77 (544,304) Brain Any BD 2.2 (1.04–4.0)d Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.
Mili et al., 1993
[29]
3 (10,891) 52 (241,473) Brain Any BD 2.1 (0.4–6.2)d Did not exclude any known genetic




35 (45,200) 15 (45,200) CNS Any BD 2.5 (1.8–3.4)c Did not exclude any known genetic
syndromes. O/E ratio is age
standardized.
NA NA CNS Other nervous system 5.7 (2.7–11.9)g
Rankin et al.,
2008 [30]




35 (115,686) 394 (3,071,255a) CNS Any BD 1.11 (0.76–1.57)f Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
Fisher et al.,
2012 [36]
34 (59,258) NR CNS Non-chromosomal 1.80 (1.28–2.53)e
3 (6,327) NR CNS Chromosomal 1.87 (0.60–5.79)e
Botto et al.,
2013 [32]
16 (44,151) 38 (147,940) Brain Structural 1.74 (1.0–3.1)f Children with chromosomal anomalies
were excluded.5 (44,151) 17 (147,940) AST Structural 1.22 (0.4–3.33)f
<5 (44,151) 13 (147,940) MB Structural 1.27 (0.4–3.9)f
7 (44,151) 8 (147,940) Other brain Structural 3.62 (1.3–10)f
Sun et al., 2014
[38]
9 (4,484) 28 (1,547,126) CNS (<1 year) Nervous system (cohort
entry on day of birth)
111.2 (52.46–
235.61)e
Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.NR (NR) NR (NR) CNS (<1 year) Nervous system (cohort
entry at BD diagnosis)
87.98 (31.06–
249.20)e
17 (4,484) 330 (1,547,126) CNS (1–15 years) Nervous system (cohort
entry on day of birth)
17.11 (10.51–27.86)e
NR (NR) NR (NR) CNS (1–15 years) Nervous system (cohort
entry at BD diagnosis)
13.21 (7.24–24.08)e
1 (4,484) 28 (1,547,126) CNS (<1 year) Circulatory system
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Cancer type Birth defect Risk estimate (95%
CI)
Comments
NR (NR) NR (NR) CNS (<1 year) Circulatory system
(cohort entry at BD
diagnosis)
2.36 (0.33–17.08)e
13 (4,484) 330 (1,547,126) CNS (1–15 years) Circulatory system
(cohort entry on day of
birth)
2.56 (1.47–4.45)e
NR (NR) NR (NR) CNS (1–15 years) Circulatory system





14 (32,273) 207a (608,276) CNS cancer and
intracranial/spinal
N BDs 1.26 (0.74–2.17)e Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).16 (32,273) 215a (608,276) CBT N BDs 1.39 (0.84–2.31)e
Janitz et al.,
2016 [35]
11 (23,368) 91a (567,867) CNS Any BD (w/chromosomal) 3.1 (1.6–5.7)e† HRs were estimated at each age.
The authors note that the proportional
hazards assumption was not met for the
overall association and that a
continuous time interaction model was
used for those noted with an ‘†’.
NA NA CNS (<1 year) Any BD (w/chromosomal) 17.9 (3.5–91.5)e
NA NA CNS (3 years) Any BD (w/chromosomal) 3.6 (1.9–6.8)e
NA NA CNS (6 years) Any BD (w/chromosomal) 1.9 (0.8–4.5)e
NA NA CNS (9 years) Any BD (w/chromosomal) 1.3 (0.4–4.0)e
NA NA CNS (12 years) Any BD (w/chromosomal) 1.0 (0.3–3.8)e
10 (22,109a) 91a (567,867) CNS Non-chromosomal 2.9 (1.5–5.6)e†
NA NA CNS (<1 year) Non-chromosomal 25 (4.8–130.0)e
NA NA CNS (3 years) Non-chromosomal 3.4 (1.7–6.7)e
NA NA CNS (6 years) Non-chromosomal 1.6 (0.6–4.1)e
NA NA CNS (9 years) Non-chromosomal 1.0 (0.3–3.4)e
NA NA CNS (12 years) Non-chromosomal 0.7 (0.2–3.1)e
Central nervous system and miscellaneous intracranial and intraspinal neoplasms nested case-control studies
Linet et al., 1996
[63]
570 (25) 2,850a (129) Brain Any BD 1.0 (0.6–1.5)b Estimates adjusted for matching
variables.205 (8) 1,025a (46) Low grade AST Any BD 0.9 (0.4–1.8)b
58 (3) 290a (16) High grade AST Any BD 0.9 (0.3–3.3)b
93 (4) 465a (23) MB Any BD 0.9 (0.3–2.6)b
54 (2) 270a (15) EPD Any BD 0.7(0.1–2.9)b
160 (8) 800a (29) Other Any BD 1.4 (0.6–3.1)b
Central nervous system and miscellaneous intracranial and intraspinal neoplasms case series with an external comparison group
Narod et al.,
1997 [53]
4,698 (167) NA Brain/Spinal Total 0.86; 0.56 Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation. The authors
note that 10 cases of hydrocephalus
occurred in CNS tumor cases, which
may be an effect rather than a cause of
the tumor.
4,698 (8) NA Brain/Spinal Spina bifida (741) 1.4 (NRCT); 3.3**
(BC)
4,698 (10) NA Brain/Spinal Hydrocephalus (7423) 2.5*; 4.0***
4,698 (7) NA Brain/Spinal Pyloric stenosis (7505) 1.4; 0.9
4,698 (6) NA Brain/Spinal Skull (7560) 1.4; 1.4
4,698 (9) NA Brain/Spinal Spine (7561) 0.98; 9.6***
4,698 (6) NA Brain/Spinal Cardiac septal 0.57; 0.29
4,698 (26) NA Brain/Spinal Genitourinary 0.65; 0.57
4,698 (12) NA Brain/Spinal Spine and rib 1.0; 8.6***
4,698 (127) NA Brain/Spinal Other 0.76; 0.46
Neuroblastoma and other peripheral nervous cell tumors case-control studies
Johnson et al.,
1985 [66]
157 (3) 314 (2) NB Any BD 3.04 (0.50–18.38)a,b The authors note that the cases and
controls had diverse BDs.
Neglia et al.,
1987 [67]
97(6) 388a(3) NB Physical anomalies 8.61 (2.00–43.86)b After removal of 4 of the 6 anomalies
identified in cases that were secondary




88 (29a) 200 (11) NB Rib 8.44 (3.98–17.93)a,b
Mann et al.,
1993 [16]
31 (4) 31 (4) NB Any BD 1.0 (0.23–4.42)a,b Matched pairs analysis
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56 (7) NR (NR) SNS Any BD 7.2 (3.0–17.1)b DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age, and maternal age.
52 (7) NR (NR) NB Any BD 7.9 (3.3–18.8)b
52 (2) NR (NR) NB Eye/face/neck 26.6 (4.3–166)b
52 (2) NR (NR) NB Gastrointestinal system 9.3 (1.9–46.1)b
52 (1) NR (NR) NB Nervous system 18.3 (1.8–184)b
Buck et al., 2001
[68]
130 (2) 301 (4) NB Any BD 1.2 (0.2–6.3)b
Merks et al.,
2005 [26]
61 (6) 881 (54) NB Cervical 1.67 (0.69–4.05)a,b
Menegaux et al.,
2005 [71]
538 (73) 504 (24) NB Any BD (ICD-10 740–
759)
2.58 (1.57–4.25)b The authors note that 9/11 eye
anomalies reported among cases were
most likely secondary to the tumor but
the overall BD association remained
unchanged when eye anomalies were
excluded. Estimates adjusted for
mother’s educational level, mother’s
race and household income at birth.
538 (23) 504 (3) NB Major 7.53 (2.23–25.5)b
538 (8) 504 (4) NB Minor 1.86 (1.06–3.25)b
538 (3) 504 (0) NB CNS (ICD-10 740–742) ND
538 (11) 504 (1) NB Eye (743) 10.9 (1.38–85.8)b
538 (15) 504 (3) NB Cardiac (745–747) 4.27 (1.22–15.0)b
538 (6) 504 (2) NB Face (749–7502) 3.40 (0.68–17.1)b
538 (7) 504 (1) NB Digestive system (7505–
751)
5.98 (0.7–50.8)b
538 (16) 504 (3) NB Genital and urinary (752–
753)
5.84 (1.67–20.4)b
538 (9) 504 (1) NB Genital (752) 10.2 (1.27–82.6)b
538 (8) 504 (2) NB Urinary (753) 4.49 (0.93–21.7)b
538 (10) 504 (6) NB Musculoskeletal (754–
756)
1.55 (0.55–4.35)b
538 (19) 538 (14) NB Other (757–759) 1.21 (0.59–2.49)b
Chow et al.,
2007 [70]
240 (23) 2,400 (116) NB Any BD 2.11 (1.32–3.40)b Major anomalies are based on Cordier
et al. [61], excluding 2 individuals with
chromosomal anomalies. Estimates
adjusted for birth year.
240 (9) 2,400 (14) NB Major only 6.86 (2.92–16.08)b
240 (5) 2,400 (9) NB Cardiac only 5.84 (1.93–17.66)b
240 (2) 2,400 (25) NB Urogenital only 0.85 (0.20–3.62)b
Urayama et al.,
2007 [73]
508 (33) 1,015 (39) NB Any BD 1.77 (1.09–2.88)b The OR = 1.77 is unadjusted. Other
estimates adjusted for race/ethnicity,
gestational age/ birth weight index,
percentage of the adult population with
a college degree, initiation of prenatal
care, type of delivery and maternal
pregnancy history.
NR NR NB Any BD 1.53 (0.87–2.68)b
228 (NR) NR NB (<1 year) Any BD 1.57 (0.76–3.27)b
102 (NR) NR NB (1–4 years) Any BD 1.04 (0.41–2.68)b
Munzer et al.,
2008 [69]
191 (12) 1,681 (57) NB Any BD 2.2 (1.1–4.5)b Estimates adjusted for age and gender.
191 (2) 1,681 (19) NB Minor BD 1.7 (0.4–7.7)b
191 (10) 1,681 (38) NB Major BD 2.4 (1.1–5.4)b
191 (0) 1,681 (5) NB Heart -
191 (1) 1,681 (2) NB Digestive 4.6 (0.3–69)b
191 (4) 1,681 (10) NB Urinary 4.4 (1.1–17)b
191 (1) 1,681 (6) NB Genital organs 1.7 (0.2–15.0)b
191 (5) 1,681 (22) NB Skeleton 3.3 (1.1–9.6)b
191 (14) 1,681 (2) NB Others 0.7 (0.1–5.7)b
74 (7) 187 (2) NB (<1 year) Any BD 16.8 (3.1–90)b
74 (7) 187 (1) NB (<1 year) Major BD 31.3 (3.6–272)b
74 (0) 187 (1) NB (<1 year) Minor BD -
117 (5) 1,494 (55) NB ( 1 year) Any BD 1.0 (0.3–2.9)b
117 (3) 1,494 (37) NB ( 1 year) Major BD 1.9 (0.4–8.6)bb
117 (2) 1,494 (18) NB ( 1 year) Minor BD 0.7 (0.2–3.0)b
Zierhut et al.,
2011 [24]
31 (2) 1,133 (51) NB and other peripheral
nervous cell tumors
Abnormal ribs 1.48 (0.34–6.40)b Estimates adjusted for sex and age.
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153 (7) 1,044 (14) NB Any BD 4.9 (1.8–13.6)b Estimates adjusted for gender, age,
area of residence, maternal age, and
maternal level of education.
Rios et al., 2016
[74]
357 (13) 1783 (47) NB Any BD 1.6 (0.8–3.0)b Estimates adjusted for age and sex,
birth order, maternal age, urban status
of the area of residence and study
357 (10) 1783 (43) NB 1 BD 1.3 (0.6–2.6)b
357 (3) 1783 (4) NB 2 BD 6.3 (1.3–29)b
188 (9) 544 (9) NB (<18 months) Any BD 3.6 (1.3–8.9)b
188 (8) 544 (9) NB (<18 months) 1 BD 2.9 (1.1–7.9)b
188 (1) 544 (0) NB (<18 months) 2 BD -
169 (4) 1239 (38) NB (18 months) Any BD 0.8 (0.3–2.3)b
169 (2) 1239 (34) NB (18 months) 1 BD 0.4 (1.1–1.8)b
169 (2) 1239 (4) NB (18 months) 2 BD 4.1 (0.7–23.3)b
357 (1) 1783 (13) NB Cardiovascular -
357 (1) 1783 (1) NB Digestive -
357 (6) 1783 (15) NB Genitourinary 2.2 (0.8–6.0)b
357 (3) 1783 (14) NB Skeleton -
357 (1) 1783 (0) NB CNS -
357 (1) 1783 (4) NB Head and neck -
Neuroblastoma and other peripheral nervous cell tumors cohort studies
Windham et
al.,1985 [27]
2 (22,856) NR (NR) NB Any BD 1.1 (0.4–3.4)c Did not exclude any known genetic
syndromes. Estimates are age
standardized.
NR (NR) NR (NR) NB Any BD (Male) 1.1c
NR (NR) NR (NR) NB Any BD (Female) 1.3c
NR (NR) NR (NR) NB (0–4 years) Any BD (Male) -
NR (NR) NR (NR) NB (0–4 years) Any BD (Female) 1.3c
NR (NR) NR (NR) NB (5–9 years) Any BD (Male) 6.3c
NR (NR) NR (NR) NB (5–9 years) Any BD (Female) -
Mili et al., 1993
[28]
4 (19,373) 5 (544,304) NB Any BD 20.3 (5.5–52.1)d Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.
Mili et al., 1993
[29]
2 (10,891) 32 (241,473) NB Any BD 2.2 (0.3–7.9)d Did not exclude any known genetic




14 (45,200) 7 (45,200) SNS Any BD 2.2 (1.4–3.4)c Did not exclude any known genetic
syndromes. O/E ratio is age
standardized









8 (178a) NR NB Any BD 2.3 (1.2–4.8)e
5 (83a) NR Adrenal medulla NB Any BD 3.2 (1.3–7.8)e
3 (95a) NR Non-adrenal medulla
NB
Any BD 1.6 (0.5–5.1)e
Carozza et al.,
2012 [31]
31 (115,686) 274 (3,071,225a) NB Any BD 1.43 (0.94–2.10)f Genetic syndromes were not excluded.
Excluding subjects with chromosomal
anomalies resulted in a lower IRR for




15 (59,258) NR NB Non-chromosomal 2.85 (1.69–4.78)e
1 (6,327) NR NB Chromosomal 2.08 (0.29–14.82)e
Botto et al.,
2013 [32]
11 (44,151) 17 (147,940) NB spectrum Structural 2.68 (1.3–5.7)f Children with chromosomal anomalies
were excluded.8 (44,151) 15 (147,940) NB Structural 2.21 (0.9–5.2)f




Pediatric cancer risk in association with birth defects: A systematic review











5 (32,273) 66a (608,726) NB/peripheral nervous
system tumors
N BDs 1.41 (0.57–3.49)e Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).
Neuroblastoma and other peripheral nervous cell tumors case-cohort studies
Johnson et al.,
2008 [76]
2 (145a) 122 (8,217a) NB Any BD Too few cases to fit
model
Fisher’s exact test p-value = 0.92.
Neuroblastoma and other peripheral nervous cell tumors case series with an external comparison group studies
Narod et al.,
1997 [53]
1,208 (71) NA NB Total 1.4** (NRCT); 0.93
(BC)
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.
1,208 (5) NA NB Ear, head, and neck (ICD-
9 code 744)
3.3*; 2.2
1,208 (2) NA NB Branchial cleft (7444) 8.3*; 9.5*
1,208 (3) NA NB Septal defects (745) 1.1; 0.57
1,208 (2) NA NB Tetralogy of Fallot (7452) 8.3*; 3.8
1,208 (2) NA NB Pulmonary valve 5.5; 3.9
1,208 (2) NA NB Other aorta 6.7; 118***
1,208 (3) NA NB Cleft lip or palate 2.9; 1.3
1,208 (9) NA NB Gastrointestinal (750–51) 3.1**; 2.4*
1,208 (4) NA NB Pyloric stenosis (7505) 3.1*; 2.0
1,208 (2) NA NB Imperforate anus (7512) 3.7; 4.7
1,208 (15) NA NB Genitourinary (752–53) 1.5; 1.3
1,208 (20) NA NB Musculoskeletal (754–56) 3.0***; 1.4
1,208 (8) NA NB Foot deformity (7545–47) 3.3**; 1.4
1,208 (4) NA NB Spinal (7561) 1.7; 16.7***
1,208 (4) NA NB Cardiac septal 1.5; 0.76
1,208 (5) NA NB Spine and rib 1.7; 14.3***
1,208 (12) NA NB Other 0.48; 0.33
1,208 (16) NA NB and other
sympathetic
Genitourinary 1.5; 1.3
Retinoblastoma and eye tumor case-control studies
Mann et al.,
1993 [16]
6 (0) 6 (1) RB Any BD - Not significant (Fisher ‘s test)
Altmann et al.,
1998 [17]
26 (5) NR (NR) RB Any BD 15.0 (5.1–44.2)b DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age and maternal age.
26 (2) NR (NR) RB All chromosomal 54.8 (7.7–391)b
Retinoblastoma and eye tumor cohort studies
Windham et al.,
1985 [27]
2 (22,856) NR (NR) Eye Any BD 2.3 (0.6–8.7)c Did not exclude any known genetic
syndromes. Estimates are age
standardized.
NR (NR) NR (NR) Eye Any BD (Male) 2.4c
NR (NR) NR (NR) Eye Any BD (Female) 2.2c
NR (NR) NR (NR) Eye (0–4 years) Any BD (Male) 2.5c*
NR (NR) NR (NR) Eye (0–4 years) Any BD (Female) 2.2c
NR (NR) NR (NR) Eye (5–9 years) Any BD (Male) -
NR (NR) NR (NR) Eye (5–9 years) Any BD (Female) -
Mili et al., 1993
[28]
4 (19,373) 22 (544,304) RB Any BD 4.7 (1.3–12.1)d Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.
Agha et al.,
2005 [33]
4 (45,200) 2 (45,200) RB Any BD 2.2 (0.9–5.1)c Did not exclude any known genetic
syndromes. O/E ratio is age
standardized.
NA NA RB Chromosomal 10.8 (1.4–71.1)g
NA NA RB Anomalies of the eye 14.3 (2.0–99.1)g
Rankin et al.,
2008 [30]
2 (NR) 32a (NR) RB Any BD 3.73 (0.99–14.10)f Did not exclude any known genetic
syndromes.
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13 (115,686) 125 (3,071,255a) RB Any BD 2.34 (1.21–4.16)f Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
Botto et al.,
2013 [32]




0 (32,273) 35 (608,726) RB N BDs 0e Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).
Retinoblastoma and eye tumor case series with an external comparison group studies
Narod et al.,
1997 [53]
549 (36) NA RB Total 1.6 (NRCT); 1.0 (BC) Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.
549 (2) NA RB Cataract (743) 12.5*; 16.6*
549 (5) NA RB Ventricular septal (7454) 6.1*; 4.5*
549 (3) NA RB Other heart (746) 3.5; 2.6
549 (5) NA RB Gastrointestinal (750–
751)
3.8*; 1.8
549 (5) NA RB Genitourinary (752–53) 1.1; 0.88
549 (8) NA RB Musculoskeletal (754) 2.7*; 1.3
549 (5) NA RB Cardiac septal 4.1*; 2.1
549 (5) NA RB Genitourinary 1.1; 0.94
549 (0) NA RB Spine and rib 0; 0
549 (8) NA RB Other 0.67; 0.46
Renal tumors case-control studies
Wilkins et al.,
1984 [77]
105 (NR) 210a (NR) WT Any BD NR The authors noted that the BD




88 (10) 88 (NR) WT Wilms’-associated 1.5 (0.3–8.3)b
88 (13) 88 (NR) WT Non-Wilms’-associated 4.3 (1.0–27.6)b
Kajta´r et al.,
1990 [79]
34 (13) 148 (41) WT Total vertebral 1.62 (0.74–3.52)a,b
34 (5) 148 (5) WT Spina bifida occulta





68 (16a) 200 (11) WT Rib 5.29 (2.31–12.09)a,b
Mann et al.,
1993 [16]
32 (5) 32 (1) WT Any BD 5.74 (0.63–52.24)a,b Not significant (Fisher’s test)
Altmann et al.,
1998 [17]
42 (4) NR (NR) Renal Any BD 4.6 (1.6–13.8)b DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age, and maternal age.
40 (4) NR (NR) WT Any BD 4.9 (1.6–14.5)b
40 (1) NR (3) WT Eye/face/neck 18.9 (1.9–190)b
40 (1) NR (5) WT All chromosomal 15.7 (1.7–153)b
Me´hes et al.,
2003 [80]
50 (9) 180 (8) WT Spina bifida occulta 4.72 (1.72–12.98)a,b
50 (16) 180 (46) WT Total vertebral 1.37 (0.69–2.71)a,b





133 (13) 881 (54) WT Cervical 1.66 (0.88–3.13)a,b
Zierhut et al.,
2011 [24]
20 (3) 1,133 (51) Renal Abnormal ribs 3.73 (1.05–13.22)b Estimates adjusted for sex and age.
Renal tumors cohort studies
Windham et al.,
1985 [27]
4 (22,856) NR (NR) Renal Any BD 2.2 (0.9–5.7)c Did not exclude any known genetic
syndromes. Estimates are age
standardized.
NR (NR) NR (NR) Renal Male -
NR (NR) NR (NR) Renal Female 4.8c*
NR (NR) NR (NR) Renal (0–4 years) Male -
NR (NR) NR (NR) Renal (0–4 years) Female 4.3c*
NR (NR) NR (NR) Renal (5–9 years) Male -
NR (NR) NR (NR) Renal (5–9 years) Female 6.7c
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Cancer type Birth defect Risk estimate (95%
CI)
Comments
Mili et al., 1993
[28]
4 (19,373) 38 (544,304) WT Any BD 2.8 (0.7–7.1)d Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses. Minor
defects were included only if they were












14 (115,686) 172 (3,071,255a) Renal Any BD 1.11 (0.59–1.91)f Genetic syndromes were not excluded.
Excluding subjects with chromosomal
anomalies resulted in a lower IRR for




6 (59,258) NR WT Non-chromosomal 1.45 (0.65–3.26)e
5 (6,327) NR WT Chromosomal 13.43 (5.54–32.55)e
Botto et al.,
2013 [32]
<5 (44,151) 16 (147,940) Kidney Structural 1.03 (0.3–3.1)f Children with chromosomal anomalies
were excluded.<5 (44,151) 15 (147,940) WT Structural 1.10 (0.4–3.3)f
0 (44,151) <5 (147,940) Other kidney Structural 0
Dawson et al.,
2015 [34]
6 (32,273) 55 (608,726) Renal N BDs 2.02 (0.87–4.69)e Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).
Renal tumors case-cohort studies
Puumala et al.,
2008 [82]
7 (138a) 124 (8,752a) WT Any BD 3.20 (1.37–7.47)e Estimate adjusted for sex and birth
year.
Renal tumors nested case-control studies
Lindblad et al.,
1992 [81]
110 (NR) 550 (NR) WT Any BD NR The authors note that reported BD
associations were not confirmed.
Renal tumors case series with an external comparison group studies
Breslow et al.,
1982 [83]




WT CNS 1.12 (CPP); 2.47
(CDC)a,c
The ratio of the rates in NWTS versus
the CPP and Atlanta are represented.
WT Aniridia (743.45) 840; 420a,c
WT Eye, excluding aniridia
cases (743)
0.93–1.48; 4.11a,c




WT Cleft palate-lip (749) 0.4; 0.42a,c
WT Upper alimentary tract-
digestive system (750–1)
0.92–1.19; 1.94a,c
WT Cryptorchidism (752.5) 0.6–2.33; 1.5a,c
WT Hypospadias (752.6) 2.05; 3.63a,c
WT Genital (752, excluding
752.5 and 752.6)
0.6–2.33; 1.5a,c













WT Hair skin and nails (757) 0.48; 7.74a,c
WT Chromosome defects, DS
(758)
0.45; NDa,c
WT Accessory spleen (759.0) 31.5; NDa,c
WT Hemihypertrophy (759.8) 823.33; NDa,c
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1,148 (106) NA WT Total 2.2***(NRCT);
1.5***(BC)
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.
1,148 (3) NA WT Spina bifida (741) 1.4; 5.0*
1,148 (2) NA WT Microcephaly (7421) 3.2; 5.7
1,148 (2) NA WT Transposition of the great
vessels (7451)
11.8*; 4.4
1,148 (7) NA WT Ventricular septal (7454) 4.1**; 3.0*
1,148 (2) NA WT Congenital aortic stenosis
(7463)
4.3; 15.4*
1,148 (3) NA WT Pyloric stenosis (7505) 2.5; 1.6
1,148 (2) NA WT Ovary (7520) 18.2*; 25.0**
1,148 (2) NA WT Uterus (7523) 11.8**; 100***
1,148 (8) NA WT Cryptorchidism (7525) 2.2; 2.7*
1,148 (5) NA WT Hypospadias (7526) 2.9; 1.9
1,148 (14) NA WT Urinary system (753) 3.7***; 58.3***
1,148 (5) NA WT Congenital hip dislocation
(7543)
2.5; 1.4
1,148 (3) NA WT Lower limb (7556) 2.1; 10.3**
1,148 (2) NA WT Skull and facial bones
(7560)
1.9; 2.0
1,148 (3) NA WT Spinal (7561) 1.3; 13.0**
1,148 (2) NA WT Chondrodystrophy (7564) 8.7*; 7.4
1,148 (3) NA WT Spina bifida 2.2; 5.0*
1,148 (10) NA WT Cardiac septal 4.1***; 2.0
1,148 (29) NA WT Genitourinary 2.9***; 2.6***
1,148 (4) NA WT Spine and rib 1.4; 12.1***
1,148 (41) NA WT Other 1.6**; 0.74
NR (2) NA Renal carcinoma Spine and rib 37**; 339***
Hepatic tumors case-control studies
Mann et al.,
1993 [16]
6 (2) 6 (0) HB Any BD - Not significant (Fisher’s exact test)
Altmann et al.,
1998 [17]
7 (1) NR (NR) Hepatic Any BD 9.3 (0.9–94.2) DS cases were not excluded. Estimates
adjusted for 6-month calendar period,






387 (1); 290 (0) HB Cleft lip or palate COG: 1.05 (0.07–
16.9)b; UPDB: -
Excluded children with Beckwith-
Wiedemann Syndrome and familial
adenomatous polyposis.
COG estimates adjusted for sex; UPDB
estimates adjusted for birth weight,
maternal age, and maternal education.
387 (4); 29 (0) 387 (2); 290 (0) HB Spina bifida or other
spinal
2.12 (0.39–11.7)b; -
387 (37); 29 (0) 387 (30); 290 (1) HB Large/multiple birth marks 1.33 (0.81–2.21)b; -
387 (1); 29 (0) 387 (0); 290 (0) HB Trisomy 18 -; -
387 (2); 29 (0) 387 (1); 290 (0) HB Other genetic conditions 2.11 (0.19–23.4)b; -
387 (0); 29 (0) 387 (1); 290 (1) HB Down syndrome -
387 (1); 29 (1) 387 (0); 290 (1) HB Rib -; 4.3 (0.23–80.0)b
387 (3); 29 (0) 387 (0); 290 (0) HB Small head/microcephaly -; -




387 (4); 29 (0) 387 (2); 290 (1) HB Hypospadias 2.1 (0.38–11.4)b;
<0.001 (NA)b
387 (12); 29 (2) 387 (3); 290 (0) HB Any kidney/bladder 4.3 (1.2–15.3)b; >99
(NA)b
387 (6); 29 (1) 387 (5); 290 (1) HB Sex organ 1.24 (0.37–4.1)b; 25.7
(1.63, >99)b
NR; 29 (2) NR; 290 (2) HB Heart or pulmonary -; 7.4 (0.87–62.7)b
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Cancer type Birth defect Risk estimate (95%
CI)
Comments
Hepatic tumors cohort studies
Agha et al.,
2005 [33]
3 (45,200) 0 (45,200) Hepatic Any BD - Did not exclude any known genetic
syndromes. O/E ratios are age
standardized.
NA NA Hepatic Other anomalies of the
digestive system
11.7 (2.9–46.7)g
NA NA Hepatic Chromosomal 8.0 (1.1–56.8)g
Carozza et al.,
2012 [31]
16 (115,686) 45 (3,071,255a) Liver Any BD 1.00 (0.52–1.83)f Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
Botto et al.,
2013 [32]
8 (44,151) <5 (147,940) Liver Structural 16.54 (3.5–77.9)f Children with chromosomal anomalies
were excluded.7 (44,151) <5 (147,940) HB Structural 14.47 (3.0–69.7)f
<5 (44,151) 0 (147,940) Other liver Structural -
Dawson et al.,
2015 [34]
4 (32,273) 10a (608,726) Hepatic N BDs 7.54 (2.36–24.03)e Excluded syndromes known to be




5 (23,368) <9a (567,867) Hepatic Any BD (w/chromosomal) 25.0 (7.2–86.2)e The exact number of hepatic tumor
cases was suppressed.5 (22,109a) <9a (567,867) Hepatic Non-chromosomal NR
Hepatic tumors case-cohort studies
Spector et al.,
2008 [85]
5 (36a) 112 (7,788a) HB Any BD 5.87 (1.88–18.3)e Adjusted for birth weight, birth year, and
sex.
Hepatic tumors case series with an external comparison group studies
Narod et al.,
1997 [53]
NR (2) NA HB Spina bifida 2.0 (NRCT); 4.7 (BC) Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.
165 (3) NA Liver Genitourinary 2.1; 1.9
165 (0) NA Liver Spine and Rib 0; 0
Malignant bone tumors case-control studies
Schumacher et
al., 1992 [23]
55 (3a) 200 (11) OS Rib 0.99 (0.27–3.68)a,b
35 (6a) 200 (11) ES Rib 3.55 (1.22–10.35)a,b
Mann et al.,
1993 [16]
30 (3) 30 (2) Bone Any BD 1.56 (0.24–10.05)a,b
Gelberg et al.,
1997 [12]




8 (2) NR (NR) Bone Any BD 23.2 (3.8–143)b DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age, and maternal age.
8 (1) NR (5) Bone All chromosomal 28.6 (2.9–280)b
Merks et al.,
2005 [26]
48 (3) 881 (54) OS Cervical 1.02 (0.31–3.39)a,b
39 (3) 881 (54) ES Cervical 1.28 (0.38–4.28)a,b
Durmaz et al.,
2011[20]
23 (20a) 200 (70a) OS Any Minor 12.4 (3.6–42.1)a,b Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported.
Zierhut et al.,
2011 [24]
39 (2) 1,133 (51) Bone Abnormal ribs 0.95 (0.21–4.31)b
21 (2) 1,133 (51) OS Abnormal ribs 1.81 (0.38–8.53)b
15 (0) 1,133 (51) ES and related
sarcomas of bone
Abnormal ribs -




Malignant bone tumors cohort studies
Agha et al.,
2005 [33]
6 (45,200) 5 (45,200) Bone Any BD 1.3 (0.7–2.4)c Did not exclude any known genetic
syndromes. O/E ratio is age
standardized.
NA NA Bone Other musculoskeletal 4.3 (1.1–17.3)g
Carozza et al.,
2012 [31]
1 (115,686) 19 (3,071,255a) Bone Any BD 0.63 (0.02–3.99)f Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
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0 (44,151) <5 (147,940) OS Structural - Children with chromosomal anomalies
were excluded.<5 (44,151) <5 (147,940) ES Structural 2.07 (0.2–22.8)f
Dawson et al.,
2015 [34]
2 (32,273) 32a (608,726) Bone N BDs 1.19 (0.29–4.96)e Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).
Malignant bone tumors case series with an external comparison group studies
Narod et al.,
1997 [53]
NR (1) NA Bone Spina bifida 20.0 (NRCT); 50.0*
(BC)
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.
396 (26) NA ES Total 1.58; 1.0
396 (2) NA ES Spina bifida (741) 4.3; 9.5*
396 (2) NA ES Cataracts (7433) 14.3*; 23.0**
396 (2) NA ES Orbit (7436) 8.3; 13.3*
396 (5) NA ES Genitourinary (752–3) 1.5; 1.2
396 (10) NA ES Musculoskeletal (754–6) 2.0; 1.4
396 (2) NA ES Spinal (7561) 2.6; 25.3**
396 (2) NA ES Osteodystrophy (7565) 33.9**; 41.7**
396 (5) NA ES Other 0.70; 0.37
396 (1) NA ES Cardiac septal 1.1; 0.58
396 (5) NA ES Genitourinary 1.5; 1.3
549 (1) NA OS Genitourinary 0.21; 0.19
NR (6) NA Bone Spine and rib 2.4; 22.2***
Soft tissue and other extraosseous sarcomas case-control studies
Schumacher et
al., 1992 [23]
98 (24a) 200 (11) STS Rib 5.57 (2.60–11.95)a,b
Mann et al.,
1993 [16]
43 (6) 43 (1) STS Any BD 6.81 (0.78–59.22)a,b
Savitz et al.,
1994 [15]
26 (3) 212 (11) STS Major 2.4 (0.6–9.4)b
Yang et al.,
1995 [86]
249a (56) 302 (55) RMS Any BD 1.3 (0.85–2.02)b
249a (15) 302 (8) RMS Major 2.36 (0.92–6.18)b
249a (36) 302 (46) RMS Minor 0.94 (0.57–1.55)b
Altmann et al.,
1998 [17]
43 (3) NR (NR) STS Any BD 3.5 (1.0–11.8)b DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age and maternal age.
23 (3) NR (NR) RMS Any BD 7.9 (2.2–28.8)b
23 (1) NR (9) RMS Genitourinary 18.2 (2.1–157)b
Merks et al.,
2005 [26]
68 (5) 881 (54) RMS Cervical 1.22 (0.47–3.15)a,b
Durmaz et al.,
2011[20]
11 (11a) 200 (70a) RMS Any BD 1 (ND-1)a,b Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported.
Zierhut et al.,
2011 [24]
30 (1) 1,133 (51) STS and other
extraosseous sarcomas
Abnormal ribs 0.64 (0.08–4.91)b Estimates adjusted for sex and age.
15 (1) 1,133 (51) RMS Abnormal ribs 1.35 (0.17–10.62)b
15 (0) 1,133 (51) Other specified or
unspecified STS
Abnormal ribs -
Soft tissue and other extraosseous sarcomas cohort studies
Mili et al., 1993
[29]
2 (10,891) 18 (241,473) Sarcoma Any BD 4.1 (0.5–14.8)d Did not exclude any known genetic
syndromes. Estimates adjusted for age
and sex. Minor defects were included








2 (NR) 40a (NR) RMS Any BD 2.98 (0.77–11.52)f Did not exclude any known genetic
syndromes. RMS includes other STS as
noted in a table footnote.
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15 (115,686) 102 (3,071,225a) STS Any BD 2.12 (1.09–3.79)f Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
Fisher et al.,
2012 [36]
6 (59,258) NR RMS Non-chromosomal 2.26 (1.00–5.11)e
0 (6,327) NR RMS Chromosomal -
Botto et al.,
2013 [32]
<5 (44,151) 5 (147,940) RMS Structural 3.31 (0.9–12.3)f Children with chromosomal anomalies
were excluded.0 (44,151) <5 (147,940) Fibrosarcoma Structural -
<5 (44,151) <5 (147,940) Other STS Structural 1.38 (0.1–13.8)f
Sun et al., 2014
[38]
1 (4,484) 33 (1,547,126) Mesothelial and soft
tissue (<1 year)
Nervous system (cohort
entry on day of birth)
10.47 (1.43–76.58)e Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.NR (NR) NR (NR) Mesothelial and soft
tissue (<1 year)
Nervous system (cohort
entry at BD diagnosis)
24.22 (3.30–177.63)e
5 (4,484) 87 (1,547,126) Mesothelial and soft
tissue (1–15 years)
Nervous system (cohort
entry on day of birth)
19 (7.72–46.81)e
NR (NR) NR (NR) Mesothelial and soft
tissue (1–15 years)
Nervous system (cohort
entry at BD diagnosis)
23.02 (9.34–56.72)e
2 (24,643) 33 (1,547,126) Mesothelial and soft
tissue (<1 year)
Circulatory system
(cohort entry on day of
birth)
3.81 (0.91–15.86)e
NR (NR) NR (NR) Mesothelial and soft
tissue (<1 year)
Circulatory system
(cohort entry at BD
diagnosis)
-
4 (4,484) 874 (1,547,126) Mesothelial and soft
tissue (1–15 years)
Circulatory system
(cohort entry on day of
birth)
2.99 (1.10–8.14)e
NR (NR) NR (NR) Mesothelial and soft
tissue (1–15 years)
Circulatory system





2 (32,273) 53a (608,726) STS N BDs 0.71 (0.17–2.90)e Excluded syndromes known to be




5 (23,368) <30a (567,867) STS Any BD (w/chromosomal) 3.7 (1.3–10.6)e The exact number of STS cases was
suppressed.5 (22,109a) <30a (567,867) STS Non-chromosomal 3.9 (1.4–11.2)e
Soft tissue and other extraosseous sarcomas case series studies with an external comparison group studies
Ruymann et al.,
1988 [87]





Authors presented rates for two external
comparison groups: 1) the NWTS and
2) the CPP. Rate ratios were calculated
as the ratio of the rate in study
population to the rate in the external
comparison group.
9 (115) NR (1,905);
NR (53,257)
RMS CNS 16.64 a,c; 18.62 a,c
13 (115) NR (1,905);
NR (53,257)
RMS Upper alimentary tract/
digestive systems
7.68 a,c; 7.05 a,c
4 (115) NR (1,905);
NR (53,257)
RMS Cardiopulmonary 2.68 a,c; 4.26 a,c
5 (115) NR (1,905);
NR (53,257)
RMS Accessory spleens 6.9 a,c; 217 a,c
NR (115) NR (1,905);
NR (53,257)
RMS Musculoskeletal 0.38 a,c; 0.31 a,c
NR (115) NR (1,905);
NR (53,257)
RMS Aniridia ND
NR (115) NR (1,905);
NR (53,257)
RMS Hemihypertrophy 0.35 a,c; 43.5 a,c
Narod et al.,
1997 [53]
NR (2) NA RMS Cardiac septal 1.1 (NRCT); 0.56
(BC)
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.
1,248 (18) NA STS Genitourinary 1.7*; 1.5
1,248 (3) NA STS Spine and Rib 1.0; 8.3*
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Cancer type Birth defect Risk estimate (95%
CI)
Comments
Germ cell tumors, trophoblastic tumors, and neoplasms of gonads case-control studies
Swerdlow et al.,
1982 [91]
87 (2) 10,128 (NR) Testicular Genitourinary 2.99b (P = 0.15) P-values calculated by Fisher’s exact
test.87 (2) 10,128 (NR) Testicular Inguinal hernias 2.05b (P > 0.05)
Schumacher et
al., 1992 [23]
29 (1a) 200 (11) Yolk sac carcinoma Rib 0.61 (0.87–4.94)a,b
Mann et al.,
1993 [16]
41 (7) 41 (1) GCT Any BD 8.24 (0.96–70.32)a,b Pedigree was shown for one case with a
teratoma.
Shu et al., 1995
[89]
105 (NR) 639 (NR) GCT Any BD 1.4 (0.6–3.5)b
Altmann et al.,
1998 [17]
21 (4) NR (NR) Gonadal and GCT Any BD 8.9 (2.6–30.3)b DS cases were not excluded. Estimate
adjusted for 6-month calendar period,












GCT Any BD Males: 2.5 (1.3–4.9)b;
Females: 1.1 (0.7–
1.8)b
Estimates adjusted for child’s age.
82a (8), NA 180a (2), NA GCT Cryptorchidism 10.8 (2.1–55.1)b; NA








181a (7), 241 (14) GCT Large/multiple birthmarks 1.0 (0.2–4.1)b; 1.4
(0.6–2.9)b
83a (2), 195a (5) 180a (3), 241 (2) GCT Skeletal 1.6 (0.2–10.0)b; 3.1
(0.6–16.4)b
82a (5), 193a (8) 181a (5), 241 (8) GCT Other 3.0 (0.1–11.1)b; 1.3
(0.5–3.4)b
Hall et al., 2017
[90]
451 (23) 273,519 (1,527) GCT Any BD 9.12 (5.92–14.05)b Estimates adjusted for birth year and
maternal race (White v. non-White).451 (7) 273,519 (72) GCT Ear/face/neck 47.92 (21.86–
105.04)b
181 (2) 273,519 (1,527) Yolk sac tumors Any BD NR
181 (0) 273,519 (72) Yolk sac tumors Ear/face/neck -
216 (19) 273,519 (1,527) Teratomas Any BD 15.43 (9.46–25.18)b
216 (7) 273,519 (72) Teratomas Ear/face/neck 93.7 (42.14–208.32)b
Germ cell tumors, trophoblastic tumors, and neoplasms of gonads cohort studies
Agha et al.,
2005 [33]
3 (45,200) 4 (45,200) GCT, trophoblastic and
other gonadal
carcinoma & other
Any BD 0.8 (0.4–1.7)c Did not exclude any known genetic
syndromes. O/E ratio is age
standardized.
NA NA GCT Other musculoskeletal 12.9 (1.2–19.4)g
Carozza et al.,
2012 [31]
17 (115,686) 60 (3,071,225a) GCT Any BD 5.19 (2.67–9.41)f Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
Fisher et al.,
2012 [36]
8 (59,258) NR Non-CNS GCT Non-chromosomal 2.98 (1.46–6.07)e
1 (6,327) NR Non-CNS GCT Chromosomal 4.32 (0.60–30.82)e
Botto et al.,
2013 [32]
6 (44,151) 6 (147, 940) GCT, trophoblastic, and
gonadal
Structural 4.14 (1.3–12.8)f Children with chromosomal anomalies
were excluded.
<5 (44,151) <5 (147,940) Teratoma Structural 5.51 (1.2–24.6)f
<5 (44,151) <5 (147,940) Other GCT Structural 2.76 (0.5–16.5)f
Dawson et al.,
2015 [34]
2 (32,273) 28a (608,726) Gonadal and GCT N BDs 1.34 (0.32–5.63)e Excluded syndromes known to be




6 (23,368) 11a (567,867) GCT Any BD (w/chromosomal) 13.6 (5.0–36.7)e
6 (22,109a) 11a (567,867) GCT Non-chromosomal 14.3 (5.3–38.7)e
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Cancer type Birth defect Risk estimate (95%
CI)
Comments
Germ cell tumors, trophoblastic tumors, and neoplasms of gonads nested case-control studies
Wanderas et al.,
1998 [92]
32 (0) 3,028 (99) Testicular cancer Any BD - 0–4 year olds
Germ cell tumors, trophoblastic tumors, and neoplasms of gonads case series studies with an external comparison group studies
Narod et al.,
1997 [53]
544 (43) NA Gonadal and GCT Total 1.9*** (NRCT);
1.3 (BC)
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.
544 (3) NA Gonadal and GCT Other nervous (742) 3.7*; 3.2
544 (3) NA Gonadal and GCT Septal defects (745) 2.6; 1.3
544 (18) NA Gonadal and GCT Musculoskeletal (754–6) 2.7***; 1.9**
544 (6) NA Gonadal and GCT Spinal (7561) 5.7***; 54.5***
544 (1) NA Gonadal and GCT Spina bifida 1.5; 3.5
544 (6) NA Gonadal and GCT Genitourinary 1.3; 1.1
544 (6) NA Gonadal and GCT Spine and rib 4.3**; 37.5***
544 (19) NA Gonadal and GCT Other 1.4; 0.93
NR (3) NA GCT Cardiac septal 6.4*; 3.3
Other and unspecified malignant tumors case-control studies
Me´hes et al.,
1985 [19]
55 (35) Siblings: 44 (26);
Controls: 55 (17)




22 (1) 28 (0) Epithelial Any BD -
28 (1) 28 (1) Other Any BD 1.00 (0.06–16.82)a,b
Altmann et al.,
1998 [17]
7 (0) NR Carcinoma, malignant
epithelial
Any BD - DS cases were not excluded. Estimate
adjusted for 6-month calendar period,
gender, birth weight, gestational age,
and maternal age. Cases with other
malignancy types had no
malformations.
2 (0) NR Other Any BD -
Merks et al.,
2005 [26]
124 (8) 881 (54) Other Cervical 1.06 (0.49–2.28)a,b
Loder et al.,
2007 [25]
72a (10) 200 (16) Solid tumor Abnormal rib number
(normal = 24 ribs)
1.90 (0.80–4.30)b Solid tumors included WT (n = 17), OS
(n = 14), NB (n = 8), RMS (n = 5), Ewing
sarcoma (n = 3), and other types (n = 9).




14 (14a) 200 (70a) WT/GCT Any minor 1 (NR-1)a,b Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported.
12 (10a) 200 (70a) Others Any minor 9.3 (2.0–43.6)a,b
Santos et al.,
2016 [109]
281 (55) 176 (29) Solid tumor Solitary cafe´-au-lait spots 1.23 (0.75–2.02)a,b A known syndrome diagnosis was
suspected in 4 cases281 (28) 176 (12) Solid tumor Multiple cafe´-au-lait spots 1.51 (0.75–3.06)a,b
Other and unspecified malignant tumors cohort studies
Windham et al.,
1985 [27]
5 (22,856) NR (NR) Other Any BD 1.2 (0.5–3.2)c Did not exclude any known genetic
syndromes. Estimates are age
standardized.
NR (NR) NR (NR) Other Any BD (Male) 0.4c
NR (NR) NR (NR) Other Any BD (Female) 2.2c
NR (NR) NR (NR) Other (0–4 years) Any BD (Male) -
NR (NR) NR (NR) Other (0–4 years) Any BD (Female) 3.1c
NR (NR) NR (NR) Other (5–9 years) Any BD (Male) 2.2 c
NR (NR) NR (NR) Other (5–9 years) Any BD (Female) -
Agha et al.,
2005 [33]
1 (45,200) 1 (45,200) Other Any BD 1.1 (0.3–4.4)c Did not exclude any known genetic
syndromes. O/E ratios are age
standardized.
3 (45,200) 2 (45,200) Malignant epithelial Any BD 1.6 (0.6–4.0)c
NA NA Carcinomas Respiratory system 10.9 (1.5–77.2)g
NA NA Carcinomas Urinary system 11.8 (1.7–83.7)g
Rankin et al.,
2008 [30]
0 (NR) 73a (NR) All other cancers Any BD - Did not exclude any known genetic
syndromes.
(Continued)
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2 (115,686) 19 (3,071,225a) Other epithelial Any BD 2.98 (0.34–12.34)c Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.
1 (115,686) 11 (3,071,225a) Other and unspecified Any BD 5.05 (0.12–34.75)c
Botto et al.,
2013 [32]
0 (44,151) <5 (147, 940) Miscellaneous Structural ND Children with chromosomal anomalies
were excluded.
Sun et al., 2014
[38]
3 (4,484) 91 (1,547,126) Other systems (<1 year) Nervous system (cohort
entry on day of birth)
11.4 (3.61–36.0)e Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.NR (NR) NR (NR) Other systems (<1 year) Nervous system (cohort
entry at BD diagnosis)
15.73 (3.87–63.92)e
7 (4,484) 563 (1,547,126) Other systems (1–15
years)
Nervous system (cohort
entry on day of birth)
4.1 (1.95–8.65)e
NR (NR) NR (NR) Other systems (1–15
years)
Nervous system (cohort
entry at BD diagnosis)
2.84 (1.06–7.59)e
5 (4,484) 75 (1,547,126) Other systems (<1 year) Circulatory system
(cohort entry on day of
birth)
4.19 (1.69–10.35)e
NR (NR) NR (NR) Other systems (<1 year) Circulatory system
(cohort entry at BD
diagnosis)
1.57 (0.22–11.30)e
22 (4,484) 464 (1,547,126) Other systems (1–15
years)
Circulatory system
(cohort entry on day of
birth)
3.1 (2.02–4.76)e
NR (NR) NR (NR) Other systems(1–15
years)
Circulatory system





2 (32,273) 33a (608,726) Other epithelial/
melanoma
N BDs 1.17 (0.28–4.88)e Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).18 (32,273) 235a (608,726) Embryonal N BDs 1.43 (0.88–2.30)e
3 (32,273) 72a (608,726) Other N BDs 0.80 (0.25–2.53)e
Other and unspecified case series studies with an external comparison group studies
Narod et al.,
1997 [53]
NR (6) NA Carcinoma/Other Genitourinary 1.1; 1.0 Two hundred seventy-five cases with a
known genetic cause were removed;
the RR abbreviation in undefined.
NR (1) NA Carcinoma Cardiac septal 0.78; 0.40
¥For case-control and nested case-control studies the total number of cancer cases (comparison group 1) and non-cancer cases (comparison group 2) is
shown in columns 2–3 with the number in parentheses indicating the number of individuals with BDs in each comparison group. For cohort studies,
comparison group 1 is noted as above; comparison group 2 shows the number of cancer cases among the number without BDs in parentheses. For case-
cohort studies, comparison group 1 is the same as for other study designs; comparison group 2 shows the total number of individuals with cancer among the
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generally weaker associations for older children and when the follow-up period started at the
time of BD diagnosis [38].
Leukemia (Table 3)
We identified 36 articles reporting findings for associations between leukemia and hematologi-
cal malignancies and BDs.
Case-control studies (n = 24). Risk estimates ranged from 1.07 to 11.6 [15–17, 39–47] for
associations between any/major BDs and leukemia overall or specific leukemia subtypes. Shu
et al. observed no leukemia cases with BDs other than one case with Down syndrome [48].
Studies excluding DS cases from overall or sub-analyses generally reported weaker associations
[39–41, 44–46, 49]. Several studies reported positive associations between minor BDs and leu-
kemia/hematological malignancies ranging from 1.48 to 67.48 [19, 20, 45, 50–52].
Cleft lip or palate was inconsistently associated with lymphatic and myeloid leukemia [40,
43, 49]. Several studies observed positive associations between hematologic malignancies and
birthmarks [43, 46, 50] and rib anomalies [23–26]. Minor BDs of the hand, foot, eye, nose,
mouth, and ear were all positively associated with hematological malignancies in one study
[20]. Finally, inconsistent results were reported for a number of other specific BDs [41, 43, 45,
46, 53].
Cohort studies (n = 11). In six studies, positive associations were observed between leu-
kemias and any BDs/major BDs ranging from 1.1–21.97 [27–31, 33]. Associations were gener-
ally weaker in studies/analyses with DS cases were excluded [27–29, 31, 32, 34–36]. Rankin
et al. noted, however, that “the association between congenital anomalies and childhood leuke-
mia remained after exclusion of Down Syndrome cases” [30]. Notably, Dawson et al. reported
a positive association between other leukemias (types other than ALL or AML) and non-chro-
mosomal BDs [34]. Finally, Sun et al. examined nervous and circulatory system BDs and risk
of lymphatic and haematopoietic tissue malignancies in children without chromosomal anom-
alies and reported positive associations that were stronger for infants versus children 1–15
years. Associations were generally weaker when follow-up time was counted from the BD diag-
nosis rather than from birth [38].
Case series with an external comparison group studies (n = 1). Narod et al. examined a
number of specific abnormalities and did not report any consistently increased risks for leuke-
mia [53].
Lymphoma (Table 3)
We identified 17 articles reporting findings for associations between lymphoma and BDs.
Case-control studies (n = 9). Four studies reported inconsistent associations between
lymphoma/lymphoma subtypes and any BDs/major BDs with ORs ranging from 0.7–4.43
[15–17, 54]. Based on 19 lymphoma cases, Mangani et al. reported 0 lymphoma cases with
BDs [47]. Rib anomalies specifically were inconsistently associated with lymphoma subtypes
[23, 24, 26]; however, one study combining lymphoma with leukemia in their analysis reported
a significant OR of 2.0 [25].
Cohort studies (n = 7). Lymphoma was positively associated with any BD in three of four
cohort studies [30, 31, 33, 35]. Fisher et al. and Janitz et al. reported positive associations
between non-chromosomal anomalies and lymphoma [35, 36], while both Botto et al. and
Dawson et al. observed risks for lymphoma/lymphoma subtypes in both directions in children
with non-chromosomal BDs and those not known to be related to cancer [32, 34]. Certain
musculoskeletal anomalies were associated with lymphoma in one study [33].
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Case series with an external comparison group studies (n = 1). Narod et al. reported
findings for cardiac septal defects, genitourinary abnormalities, and spine and rib abnormali-
ties with a significant positive association for spine and rib abnormalities for the British
Columbia registry comparison group only [53].
CNS and miscellaneous intracranial and intraspinal neoplasms (Table 3)
We identified 31 articles reporting findings for associations between CNS tumors and BDs.
Case-control and nested case-control studies (n = 19). Risk estimates for associations
between CNS tumors and any BDs/major BDs ranged from 1.0 to 4.7 [15–17, 55–60]. Two
studies did not report risk estimates; however, one reported no association and the other
reported a decreased frequency of BDs (excluding minor BDs) in cases versus controls [61,
62]. Altmann et al. reported an increased odds of astrocytoma in children with any BD [17].
However, three studies [58, 59, 63] found weak to no evidence that children with any BD/
major BDs have an increased risk for specific CNS subtypes with the exception of other glio-
mas [58] where a 2–3 fold increased risk was reported. Importantly, these results were
unchanged after excluding seven CNS tumor cases with Neurofibromatosis Type 1 [58]. Partap
et al.’s results contrast with these findings by showing increased odds of a BD history for MBs
and PNETs compared to controls and inverse associations for gliomas [57].
Gold et al. reported a strong positive association only between brain tumors and club foot
[64]. Another study reported universally positive associations for hand, foot, eye, nose, mouth,
and ear minor BDs [20]. Birthmarks/deformities were not associated with brain tumors in one
study [65]. Altmann et al. reported highly significant and strong associations between CNS
tumors and nervous system and eye/face/neck abnormalities [17]. Finally, several investigators
reported that brain tumor cases with varying subtypes had higher odds of rib abnormalities
than controls [23–26].
Cohort studies (n = 11). Six studies reported positive associations for any BD and CNS
tumors ranging from 1.11 to 2.9 [27–31, 33]. Fisher et al. reported increased HRs for CNS
tumors in both children with and without chromosomal BDs of 1.87 and 1.80 [36]. Botto et al.
reported an increased brain tumor incidence in children with structural BDs that was stronger
for other brain tumors [32]. Dawson et al. reported a weak imprecise association of 1.26
between BDs not known to be related to cancer and CNS tumors [34]. Janitz et al. reported
increased risks in children with non-chromosomal BDs that decreased with increasing age
[35].
For specific BD types, nervous system abnormalities were strongly associated with CNS
tumors in three studies [27, 33, 38]. Finally, circulatory system malformations were positively
associated with CNS tumors in one study [38].
Case series with an external comparison group studies (n = 1). Narod et al. reported
inconsistent or inverse associations for total BD and most specific abnormalities with the
exception of hydrocephalus where both RRs were positive and significant [53].
Neuroblastoma and other peripheral nervous cell tumors (Table 3)
We identified 26 articles reporting findings for associations between NB and BDs.
Case-control studies (n = 14). Risk estimates from 11 studies reporting associations
between any BDs/physical anomalies and NB/sympathetic nervous system tumors ranged
from 1.0 to 8.61 [16, 17, 66–74]. Major and minor BDs were positively associated with NB in
four [69–71, 74] and two studies, respectively [69, 71]. Several studies examining specific BDs
generally observed positive associations [69–71], particularly for digestive system/gastrointes-
tinal and genitourinary anomalies [17, 69, 71, 74] and during infancy [69]. Rib anomalies were
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positively associated with NB/other peripheral nerve tumors in three studies to varying degrees
[23, 24, 26].
Cohort and case-cohort studies (n = 11). Children with any BD had a consistently higher
risk of NB across studies with RRs from 1.1–20.3 [27–31, 33, 75]. Fisher et al. and Botto et al.
[32, 36] also reported that non-chromosomal BDs were associated with NB and other periph-
eral nervous system tumors with individuals in the BD group having a>2-fold higher risk,
while Dawson et al. reported a lower risk estimate of 1.41 for individuals with BDs not known
to be related to cancer [34]. Finally, a case-cohort study reported a similar percentage of cases
and sub-cohort members had BDs recorded in their birth records [76]. For specific anomalies,
Agha et al. reported more observed than expected cases of SNS tumors in those with other
anomalies of the digestive system [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
results that were imprecise and in opposite directions for total BD. Generally positive associa-
tions were observed for specific BDs, particularly for cardiac and gastrointestinal abnormalities
[53].
Retinoblastoma and eye tumors (Table 3)
We identified 10 articles reporting findings for associations between RB/eye tumors and BDs.
Case-control studies (n = 2). Results were mixed with Mann et al. finding no BDs in RB
cases and Altmann et al. reporting a strong positive OR of 15.0 [16, 17]. For specific BDs,
strong associations were reported for chromosomal anomalies in a single study.
Cohort and case-cohort studies (n = 7). Of seven studies, six reported positive associa-
tions ranging from 2.2–4.7 between BDs overall or those that excluded individuals with chro-
mosomal anomalies [27, 28, 30–33]. Dawson et al. reported no RB cases [34]. Chromosomal
and eye anomalies were strongly associated with RB in one study [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
inconsistent results for associations between RB and BDs and strong associations between RB
and cataracts and ventricular septal defects [53].
Renal tumors (Table 3)
We identified 21 articles reporting findings for associations between renal tumors and BDs.
Case-control and nested case-control studies (n = 10). Wilkins et al. reported similar
frequencies of any BD in WT cases and controls [77], while two other groups reported positive
associations [16, 17]. Stronger associations were reported for non-WT associated BDs than
WT-associated BDs in one study [78]. Two studies reported significant positive associations
between WT and spina bifida [79, 80]. WT was also reported as positively associated with eye/
face/neck BDs and chromosomal BDs [17]. WT/renal carcinomas were positively associated
with rib abnormalities in three studies [23, 24, 26]. Finally, Lindblad et al. reported that associ-
ations between BDs and WT were not confirmed in a nested case-control study [81].
Cohort and case-cohort studies (n = 9). Risk estimates for cohort and case-cohort studies
examining associations between any BD and WT or renal tumors ranged from 1.0–3.2 [27, 28,
30, 31, 33, 82]. Fisher et al. reported significant risks for WT only in children with chromo-
somal BDs [36]. In two studies excluding children with chromosomal anomalies and syn-
dromes known to predispose toward cancer, results were mixed [32, 34].
Case series with an external comparison group studies (n = 2). Breslow et al. compared
the rate of different BD types in a case series to two external comparison groups and observed
consistent strongly increased rates of aniridia, double-collecting system, and hemihypertrophy
[83]. Narod et al. reported consistent findings across the two different comparison groups for
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genitourinary and reproductive organ associated BDs. Renal carcinomas were strongly associ-
ated with spine and rib malformations in one study [53].
Hepatic tumors (Table 3)
We identified 10 articles reporting associations between hepatic tumors and BDs.
Case-control studies (n = 3). There was no significant association between HB and any
BDs in one study [16], while another reported a non-significant 9.3-fold increased odds of
BDs in hepatic tumor cases versus controls [17]. For specific abnormalities, both spina bifida
and genitourinary conditions were positively associated with HB in one study [84]. Other
abnormalities were examined only in single studies.
Cohort and case-cohort studies (n = 6). One study reported three hepatic tumor cases in
individuals with BDs and none in the comparison group [33]. Carozza et al. reported no asso-
ciation between liver tumors and any BD [31], while Spector et al. reported an almost 6-fold
increased risk of HB in association with any BD [85]. Both Botto et al. and Dawson et al.
reported strongly increased IRRs for liver tumors in individuals with BDs after exclusion of
children with chromosomal BDs and syndromes known to be associated with cancer [32, 34].
In the Janitz et al. study, there were too few hepatic tumor cases to examine statistical associa-
tions [35]. Digestive and chromosomal anomalies were positively associated with hepatic
tumors in one study [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
positive associations between spina bifida and genitourinary abnormalities and HB [53].
Malignant bone tumors (Table 3)
We identified 12 articles reporting associations between BDs and bone tumors.
Case-control studies (n = 7). One study reported no association between OS and any
BDs [12]. Two studies reported positive but imprecise associations (ORs = 1.56 and 23.2)
between bone cancer and any BD [16, 17]. Minor BDs were associated with OS in one study
(OR = 12.4) [20]. One study reported a positive association between bone tumors and chromo-
somal anomalies [17]. Finally, three studies reported inconsistent associations between rib
anomalies and bone cancer (OS or ES) [23, 24, 26].
Cohort studies (n = 4). Mixed results were reported for any BD/BDs not known to be
related to cancer and bone cancer in three studies [31, 33, 34]. Botto et al. reported a two-fold
non-significant increased incidence of ES in individuals with non-chromosomal structural
BDs [32]. An ~ 4-fold excess of bone tumors was reported in children with other musculoskel-
etal BDs in one study [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
consistently strong associations using two different comparison groups between bone tumors
overall and spina bifida; however, the association was based on only one case. Strong positive
associations were also reported between osteodystrophy and cataracts and ES using both com-
parison groups [53].
Soft tissue and other extraosseous sarcomas (Table 3)
We identified 19 articles reporting associations between BDs and soft tissue and other extra-
osseous sarcomas.
Case-control studies (n = 8). Four studies reported positive associations between any
BDs/major BDs and STS/RMS ranging from 1.3 to 7.9 [15–17, 86]. Minor BDs were observed
in 100% of RMS cases and only 35% of controls in one study [20]. Further evidence for a posi-
tive association between genitourinary malformations and STS was reported for RMS [17].
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Three studies examined associations between rib anomalies and STS/RMS reporting inconsis-
tent associations [23, 24, 26]. Minor BDs were not positively associated with RMS [86].
Cohort studies (n = 9). Five cohort studies examined associations between any BDs and
STS/RMS, with all finding positive associations ranging from 1.9 to 4.1 [29–31, 33, 35]. Three
studies reported positive associations between RMS and non-chromosomal (structural) BDs,
while one study reported a non-significant inverse for STS for BDs not known to be related to
cancer [32, 34–36]. Finally Sun et al., reported strong positive associations between nervous
system BDs and mesothothelial and soft tissue cancers across age groups and weaker associa-
tions for circulatory system BDs [38].
Case series with an external comparison group studies (n = 2). One study reported
markedly higher rates of CNS anomalies, upper alimentary tract/digestive systems, cardiopul-
monary anomalies, and accessory spleens in the RMS cohort than in the two comparison
groups [87]. Narod et al. reported that genitourinary and spine and rib malformations were
positively associated with STS but this was inconsistent across comparison groups used for RR
calculations. Cardiac septal defects were not significantly associated with RMS [53].
Germ cell tumors (GCT), trophoblastic tumors, and neoplasms of
gonads (Table 3)
We identified 16 articles reporting associations between BDs and GCTs, trophoblastic tumors,
and neoplasms of gonads.
Case-control and nested case-control studies (n = 9). Several studies reported positive
associations between any BDs and gonadal tumors/GCTs ranging from 1.1 to 9.12 [16, 17, 88–
90]. Genitourinary defects and inguinal hernias were positively associated with testicular
tumors [91]. Johnson et al. reported a strong association with cryptorchidism in males [88].
Merks et al. reported an ~3-fold increased odds of cervical anomalies in GCT cases compared
to controls [26]. Hall et al. reported an increased odds of ear/face/neck anomalies in GCT
cases and those with teratomas specifically [90]. In a nested case-control study, no cases had
BDs in the 0–4 year old age group [92].
Cohort studies (n = 6). Among two cohort studies, Agha et al. reported no association
between germ cell, trophoblastic and other gonadal carcinoma and any BD, while Carozza
et al. reported a significant 5-fold increased risk [31, 33]. Fisher et al., Botto et al., and Janitz
et al. reported significant positive associations between GCTs/Gonadal and GCT and non-
chromosomal BDs, while Dawson et al. reported a weak positive association for BDs not
known to be related to cancer [32, 34–36]. GCTs were strongly associated with other musculo-
skeletal anomalies in one study [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
consistent increased risks between gonadal and GCT tumors and total BDs and weak non-sig-
nificant associations between these tumors and genitourinary defects. Musculoskeletal, spinal,
and spine and rib malformations were consistently positively associated with [53].
Other tumors (Table 3)
Several studies examined other childhood cancers and various subtype groupings for their
association with BDs. For completeness, we include these results; however, given the heteroge-
neous nature of the BDs/cancer types and outcomes examined, we do not summarize the
findings.
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Quality assessment (S2 and S3 Tables)
The mean percent total quality point score was higher for cohort (88% ± 13%) than case-con-
trol (62% ± 19%) studies. The three case-cohort study reports that were based on the same par-
ent study were of high quality each receiving 89% of the total quality points, while the three
nested case-control studies received a mean of ~85% ± 6% of the total quality points (data not
shown).
Discussion
Associations between BDs and pediatric cancer have been extensively studied. Overall conclu-
sions on pediatric cancer risk in children with BDs are limited by heterogeneity in study
design, subject selection (including inclusion/exclusion criteria), measurement, definitions,
and length of follow-up for ascertaining BDs, as well as covariate adjustment in models. For
example, in studies ascertaining individuals with BDs from BD surveillance systems, standard-
ized definitions using published classification schemes were used to group individuals with
BDs according to BD type (e.g. major, minor, and specific BD types), while for studies ascer-
taining BDs through parental questionnaire, coding schemes were often elusive. We strongly
emphasize that future studies on this topic should employ and clearly report in their methods
a standardized classification system such as that reported by Rasmussen et al. for the National
Birth Defects Prevention Study [93], which will facilitate pooling and meta-analysis studies
that are needed to more precisely quantify pediatric cancer risk in children with BDs. In spite
of the differences in methodology used by studies on this topic that limit overall conclusions,
several noteworthy findings emerged from this review.
An increased risk for pediatric cancer overall in association with BDs clearly exists with
most case-control and cohort studies reporting positive associations. A seminal Nordic study
of 5.2 million individuals, not included in our review because it did not present pediatric
cancer specific risk estimates, linked medical birth and cancer registries to examine cancer risk
in children with BDs [94]. Cancer risk was significantly increased in individuals with non-
chromosomal BDs by ~1.4–1.5 fold, with stronger risks at younger ages, which was also
reported in several studies included in this review [34, 35, 38]. Moreover, a strong association
was observed in both Norway and Sweden (>8 fold) between nervous system abnormalities
and CNS tumors [94]. Collectively, our review and the Nordic data provide strong evidence
for an overall increased cancer risk in children with BDs.
For leukemia, most studies excluding DS cases reported relatively weak or no evidence for
an increased risk of leukemia in children with any BD/major BDs. For example, when consid-
ering the results from several cohort studies with overall higher quality than case-controls
studies, generally weak associations were reported between BDs and leukemia when DS cases
were excluded [28, 29, 32, 34–36] with the exception of one study [30]. It is noteworthy that
consistent associations with rib anomalies and minor malformations have been reported in
several studies [19, 20, 23–26, 50, 52]. These data suggest that minor BDs may be linked to leu-
kemia development but most of the observed positive associations between major BDs and leu-
kemia are likely explained by inclusion of DS cases.
For CNS tumors, strong consistent associations with CNS abnormalities were reported in
several studies [17, 27, 33, 38, 53]. When interpreting these results, it is important to consider
the timing of the BD diagnosis. BDs detected only as a result of tests or procedures associated
with the tumor diagnosis may lead to over-ascertainment of BDs in cases compared to con-
trols, a potential issue raised by Altmann et al. [17]. In addition, it is also important to consider
whether the abnormality occurred secondary to the tumor, a concern noted by Narod et al. for
the association between brain/spinal tumors and hydrocephalus [53]. Evidence against these
Pediatric cancer risk in association with birth defects: A systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0181246 July 27, 2017 48 / 56
possibilities was provided by Sun et al. who reported a strong positive association between ner-
vous system abnormalities and CNS tumors when follow-up was initiated at the point of the
BD diagnosis (i.e. prior to the cancer diagnosis) [38].
For NB, many studies reported consistent positive associations with BDs overall, although
there was inconsistency for specific BD types [17, 26, 28–34, 36, 53, 66–75] with the possible
exception of gastrointestinal BDs [17, 53, 69, 71]. It is important to note that some of the
observed anomalies were noted as secondary to the tumor [67, 71]. Further research is needed
to clarify specific abnormalities associated with NB and to confirm the timing of the abnormal-
ity as congenital.
For RB/eye tumors, most cohort studies reported consistent positive associations with any
BD and structural defects [27, 28, 30–33], some of which may be explained if cases with partial
monosomy 13q were included that is associated with a number of anomalies and an increased
RB risk [95]. Since ~ 40% of RB tumors arise from a germline mutation [96], there is biological
plausibility for developmental abnormalities associated with RB haploinsufficiency. However,
despite mouse studies demonstrating lethality for embryos with Rb1-/- genotypes as well as
neural and hematopoietic abnormalities; heterozygotes did not have any observable defects
[97].
WT was associated with a number of abnormalities, some of which are due to known syn-
dromic causes of WT including Beckwith-Wiedemann and WAGR (Wilms tumor, Aniridia,
Genitourinary anomalies and intellectual disability) syndromes. WAGR syndrome is caused
by a chromosome 11p deletion and is associated with genitourinary abnormalities and aniridia
(absence of the colored part of the iris) [98]. In two recent cohort studies excluding children
with chromosomal anomalies, associations between BDs and WT were weak and imprecise
[32, 36]. It is interesting to note, however, that a greater frequency of non-WT associated BDs
were observed in children with WT versus controls in one study [78], a finding that could sug-
gest an underlying genetic predisposition.
For liver cancer, where most cases are HBs, most studies provided evidence of a positive
association with any BD [17, 32, 34, 85] that may stem from genitourinary abnormalities that
were positively associated with HB in three different study populations [53, 84]. It is unclear if
inclusion of Beckwith-Wiedemann Syndrome or Familial Adenomatous Polyposis cases in
some of studies explains the observed associations.
Although a three studies detected positive associations between BDs (especially for bone
BDs) and bone tumors or bone tumor subtypes [16, 17, 53], cohort study results are mixed
and based on small numbers [31–34]. For STSs, increased risks in children with BDs are evi-
dent from most case-control and cohort studies [15–17, 20, 29–33, 35, 36, 86]. However, as
with other cancer types, conclusions about particular abnormalities associated with risk are
limited by the heterogeneous nature of BDs observed/assessed in different studies.
For germ cell and other gonadal tumors, there is a relatively consistent pattern of an
increased risk in association with BDs across studies [16, 17, 31, 32, 34–36, 53, 88, 89] that
could be partially be due to cryptorchidism but only one study provided risk estimates in
males [88].
Although not completely consistent, one of the most intriguing findings is the observed
association between rib anomalies and many different childhood cancer types [23–26].
Although some of these associations could be due to detection bias as a result of diagnostic
tests for malignancy, the Zierhut et al. study was not subject to this type of bias [24].
The biology underlying associations between pediatric cancer and BDs is poorly under-
stood. If the observed statistical associations are causal, a leading theory is that a common
genetic abnormality impairing normal development may subsequently predispose toward
both BDs and malignancy [99–103]. Since family history is absent in most individuals with
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non-syndromic BDs, genetic aberrations could arise through de novo mutations in the parental
germline or through somatic mutations or epimutations arising early in development. For
example, Beckwith-Wiedemann syndrome, can result from genetic and epigenetic mosaicism
accompanied by a variably increased risk of malignancy (typically HB or WT) in the affected
tissues depending on the causative genetic lesion [104]. The striking number of studies show-
ing an association between rib abnormalities and pediatric/adolescent cancer risk may provide
an important clue to underlying genetic commonalities. The finding has frequently been
attributed to possible mutations in homeobox genes [25, 53] but no genetic cause has been
identified so far explaining this statistical observation.
Our study is the first systematic and most comprehensive review on this topic to date. How-
ever, there are limitations to consider. At the expense of specificity, we used broad search
terms to capture articles examining associations between BDs and pediatric cancers, identify-
ing>14,000 articles. To be as comprehensive as possible, we identified additional relevant arti-
cles through review of article references lists, IARC’s review [11], and PubMed searches.
Despite these efforts, it is still possible that we missed some eligible articles; however, it seems
unlikely that they are systematically missing and therefore their exclusion should not bias our
overall conclusions. In addition, we did not include gray literature [105] (e.g. meeting abstracts
and PhD theses) and therefore publication bias may influence general conclusions.
Conclusions and future directions
Clear positive associations exist between BDs and pediatric cancer with evidence for increased
risks for specific cancer/BD type combinations such as CNS abnormalities and CNS cancer,
rib anomalies and a number of cancer types, and genitourinary abnormalities and HB. With
advances in mutation detection through next generation sequencing technologies it may be
possible to identify genetic causes underlying some of these cases, which will provide insight
into overlaps between genes impacting both development and malignancy and provide a basis
for identification of high risk populations among children with congenital abnormalities.
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